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ABSTRACT 
 
INTRODUCTION 
 Carcinoid heart disease is acquired form of valvular heart disease occurring in 
patients with carcinoid syndrome. We sought to identify the prevalence, predictive 
biomarkers, advanced echocardiographic features, risk factors for development and 
outcomes of cardiac surgery for carcinoid heart disease. 
METHODS 
A prospective, observational, cohort study of 252 patients with a history of 
carcinoid syndrome attending a neuroendocrine tumour clinic was undertaken. 
Patients underwent serial evaluation of symptoms (cardiac and neuroendocrine), 
functional status, biochemical markers, echocardiography, and tumour staging  over 
a three year period. 
RESULTS: 
Carcinoid heart disease was initially identified in 20% of patients with 
carcinoid syndrome. The sensitivity and specificity of NT-proBNP, at a cut-off level of 
260pg/ml, for detection of carcinoid heart disease was 0.92 and 0.91, respectively. 
Involvement of the tricuspid, pulmonary, mitral and aortic valves were found in 90%, 
69%, 29% and 27% of patients respectively. Myocardial metastases were found in 
3.8% of patients. 3D echocardiography provided more detailed anatomical 
assessment, particularly for tricuspid and pulmonary valves, than 2D techniques. 
 Independent predictors of the development or progression of carcinoid heart 
disease were a 5-HIAA greater than 300 ųmol/24hr and greater than 3 episodes of 
flushing per day. Overall 30 day mortality of cardiac surgery was 18.2%. 2 year 
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survival was 44.4 %. Long term causes of death were related to advanced metastatic 
carcinoid tumour. No patient required re-operation for bio-prosthetic degeneration. 
CONCLUSION 
 The prevalence of carcinoid heart disease is significantly less than reported in 
previous decades. The high negative predictive value of NT-proBNP may allow its 
use as a screening test for carcinoid heart disease. 3D echocardiography allows 
more detailed assessment of valvulopathy than 2D techniques. A 5-HIAA > 300 
ųmol/24hr and >3 episodes of flushing per day are predictors of the development 
and/or progression of carcinoid heart disease. Cardiac valve surgery is high risk but 
provides symptomatic relief. 
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1.1 INTRODUCTION 
 
Carcinoid tumours are relatively rare neuroendocrine malignancies most 
commonly originating from enterochromaffin cells in the gastrointestinal tract. The 
incidence is approximately 1 to 2 cases per 100,000  of the general population (1). 
They usually grow slowly over years, commonly causing no symptoms at all until 
large or they have metastasised. Carcinoid tumours of midgut origin may secrete 
large amounts of vasoactive substances including 5-HT, tachykinins and 
prostaglandins. These are largely inactivated by the liver. Carcinoid syndrome 
occurs when tumour cells  metastasise to the liver as the vasoactive substances 
produced  are able to reach the systemic circulation via the hepatic vein. Clinically 
this is characterised by flushing, diarrhoea and bronchospasm.  
Over the past decade several new therapies for carcinoid tumours have 
emerged to reduce symptoms and cause tumour regression. Most notably the 
development of somatostatin analogues, which inhibit the  release of various 
biogenic amines and peptides  including serotonin, has resulted in a marked 
improvement in symptoms (2). These may also have contributed to increased 
survival although this has not been proven (2,3). Rarely, surgical resection is 
curative for non-metastatic disease. Otherwise, reduction of symptoms, improvement 
of quality of life and improvement in survival by inhibition of tumour hormones or 
reduction of tumour load are the main goals. Metastatic disease of the liver may be 
debulked either surgically or by hepatic artery embolization in selected patients. 
Interferon therapy and targeted radionuclide therapy may cause tumour stabilisation 
or regression. Chemotherapy is rarely an option except for pancreatic, bronchial and 
high grade neuroendocrine tumours. 
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Carcinoid heart disease was first reported in 1954 (4). Several series have 
reported carcinoid heart disease in up to 70% of cases of carcinoid syndrome (5,6). 
It is thought development is related to the vasoactive substances, secreted by the 
metastatic tumour cells in the liver, reaching the right heart. This is associated with 
deposition of fibrous tissue on the endocardial surfaces of the heart. The introduction 
of somatostatin analogues and other anti-tumour therapies designed to reduce the 
tumour load and the production of tumour secretory products  may potentially reduce 
the prevalence of carcinoid heart disease(7). Exceptionally, carcinoid heart disease 
may present  in carcinoid tumours without liver metastases or in primary ovarian 
carcinoid tumours where 5-HT is thought to reach systemic circulation directly, 
bypassing portal circulation and the liver (8,9).  
 
1.2 CLINICAL PRESENTATIONS 
 
 Up to 20% of patients with carcinoid syndrome present with carcinoid heart 
disease at diagnosis. It is remarkably well tolerated initially. Patients may be in 
functional NYHA class I despite severe right sided valve lesions. Eventually the  
signs and symptoms of right heart failure including shortness of breath on exertion, 
peripheral oedema and fatigue  develop as valvular dysfunction progresses. Case 
reports have demonstrated presentations due to pericardial effusions, restrictive 
cardiomyopathy (10), constrictive pericarditis (11) and patent foramen ovale 
presenting  with cyanosis and hypoxia secondary to a combination of right heart 
disease and the inter-atrial shunts (12).  
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1.3 CLINICAL EXAMINATION 
 
 Initially, clinical examination reveals prominent CV waves of tricuspid 
regurgitation, a right ventricular heave can be palpated, auscultation reveals the 
pansystolic murmur of tricuspid regurgitation, early diastolic murmur of pulmonary 
regurgitation and systolic murmur of pulmonary stenosis at the left sternal edge. 
Murmurs may be difficult to detect as velocities in the right heart are low. Peripheral 
oedema, ascites and pulsatile hepatomegaly develop as disease progresses.  
 
1.4 BIOCHEMICAL  MARKERS AND PATHOGENESIS OF CARCINOID HEART 
DISEASE 
 
The pathogenesis of the CHD and development of carcinoid plaques remains 
incompletely understood although a growing body of evidence points towards  
serotonin (5-hydroxytryptamine) playing a key role. 
  Evidence for 5-HT-induced valvulopathy has arisen from a variety of 
sources. The appetite suppressants, fenfluramine and phentermine, have been 
withdrawn because of development of valve pathology with similar  changes to those 
seen in carcinoid patients (13). These drugs display a serotonergic action on human 
tissue (14). 
Carcinoid heart valves demonstrate accumulation of tissue growth factor 
(TGF)-β latency associated peptide and latent binding protein (15). 5-HT has been 
shown to increase synthesis and up-regulate TGF-β as well as stimulating collagen 
synthesis by heart valve interstitial cells (16). These findings may contribute to the 
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pathophysiology of carcinoid heart valve involvement as 5-HT receptors are present 
in human heart valves.  
In animal models both long term 5-HT administration and the deficiency of 
5HT transporter gene can induce morphological and echocardiographic changes 
consistent with cardiac fibrosis and valvulopathy similar to those seen in human 
carcinoid heart disease (17,18). 
5-HT is metabolised to urinary 5-HIAA by monoamine oxidases in the liver. 5-
HIAA level has a high sensitivity (100%) but a very low specificity for development of 
carcinoid heart disease. Therefore it has been postulated that while 5-HT is 
important, other factors in combination with serotonin must be required of 
development of carcinoid heart disease (19). The tachykinins, neuropeptide K and 
substance P have been shown to be elevated in patients with carcinoid heart 
disease and may be an important part factor in the pathogenesis (6). In 2003, in a 
retrospective study, the Mayo Clinic analysed data from 71 patients with carcinoid 
heart disease (20). They identified peak 5-HIAA and those patients who received 
chemotherapy as risk factors for the progression of carcinoid heart disease. However 
the study was limited by retrospective analysis and possible selection bias as a large 
number of patients were excluded due to the lack of a follow up echocardiogram. 
BNP is released by the atria and ventricles  of the heart in response to wall 
stress (21). BNP is released in a variety of valvular lesions and ventricular 
dysfunction. Zuetenhorst and co-workers measured NT-proBNP in 32 patients with 
carcinoid tumours (7). Carcinoid heart disease was detected by echocardiography in 
9 patients. Significantly greater median levels of NT-proBNP were found in patients 
with carcinoid heart disease than those without.  The criterion for carcinoid heart 
disease was based on the presence of a thickened valve with grade III or greater 
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tricuspid regurgitation. Carcinoid heart disease is a heterogeneous disease affecting 
multiple valves. It remains to be established whether NT-proBNP is elevated in 
carcinoid patients with other valvular presentations.  
 
1.5 MORPHOLOGICAL  AND HISTOLOGICAL FEATURES OF CARCINOID HEART 
DISEASE 
 
 The carcinoid plaque, composed of smooth muscle cells, myofibroblasts and 
elastic tissue, forms a white fibrous layer lining the endocardial surface of cardiac 
valves superficial to normal valve tissue. Native, underlying valve morphology is 
unharmed (22). Roberts and Ross performed a necropsy study of 21 subjects with 
carcinoid heart disease and compared these to 15 patients with carcinoid syndrome 
but no heart disease. They found plaques developed on the endocardium of the right 
ventricle and atrium as well as on the valve leaflets and sub-valvular apparatus 
including chordae and papillary muscle. Deposition of plaques was also found in the 
vena cava, pulmonary artery, coronary sinus as well as coronary arteries.  The 
tricuspid valve plaques have a preponderance to develop on the ventricular side of 
the leaflets causing adherence to mural endocardium creating a substrate for 
regurgitation of blood volume. Fibrous tissue at the valve annulus causes 
constriction at the ring resulting in a degree of valvular stenosis. For the pulmonary 
valve the predominant lesion is stenosis as plaques develop at the  pulmonic root 
causing constriction of the root and diminishing an already small orifice (23,24). 
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1.6      INVESTIGATIONS  
 
1.6.1  ELECTROCARDIOGRAM AND CHEST X-RAY 
 
The ECG and Chest x-ray may provide clues in diagnosing carcinoid heart disease. 
The cardiothoracic ratio may be increased. The ECG in patients with carcinoid heart 
disease has a higher frequency of low voltage QRS complexes than in those without, 
however this finding has a low sensitivity (5,24). 
 
1.6.2 ECHOCARDIOGRAPHY 
 
 The echocardiographic features of carcinoid heart disease are well described 
(5,25). Appearances are pathognomic in the absence of exposure to the appetite 
suppressants fenfluramine and phentermine, ergot derived dopamine agonists and 
ergot alkaloid agents such as methysergide and ergotamine (13,26). 
Multiple views of each valve should be obtained for optimal evaluation of right 
sided heart valves. The tricuspid valve is visualised in parasternal long axis view of 
the right ventricular inflow tract, parasternal short axis view, apical four chamber view 
and the subcostal long axis view. The pulmonary valve is visualised in the 
parasternal long axis view of the right ventricular outflow tract, parasternal short axis 
view and subcostal short axis view (27). 
In a seminal study, Pellikka and co-workers described the two dimensional 
echocardiographic features of carcinoid heart disease identified from the 
echocardiograms of 74 patients referred to their echocardiographic laboratory (5). 
97% of patients had tricuspid valve involvement. Pulmonary valve was abnormal in 
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88% of cases. Both tricuspid and pulmonary  valve leaflets and their corresponding 
sub-valvular apparatus were found to be thickened. Excursion of the leaflets was 
reduced. In some patients valve leaflets had become retracted, fixed with lack of co-
aptation  leading to the valve remaining in a semi-open position. Functionally, a 
combination of valvular regurgitation and   stenosis occurred. A  “dagger shaped”  
continuous wave Doppler profile, due to severe tricuspid regurgitation causing early 
peak pressure and rapid decline, representing equalisation of right atrial and 
ventricular pressures was seen in severe disease (Figure 1.2 and 1.2).  The tricuspid 
valve, with or without pulmonary valve involvement, is involved in the majority of 
cases of CHD. Indeed, it is the combination of these which creates the most 
hemodynamic disturbance. Pulmonary stenosis is thought to make the severity of 
tricuspid regurgitation worse and conversely the severity of pulmonary stenosis may 
be underestimated because of low cardiac output and severe tricuspid regurgitation. 
The right atrium and ventricle are typically enlarged. As the ventricle becomes 
volume overloaded, paradoxical motion of the interventricular septum  occurs. Right 
ventricular function seemingly remains intact until quite late in the disease course. 
The increasing elevation in right ventricular pressure and increasing size of right 
atrium may lead to re-opening of patent foramen ovale in severe CHD (28). 
 Left  sided lesions occur in up to 15% of all cases (5,29).  Involvement is 
characterised by diffuse thickened of valve leaflets and is usually less severe than 
right sided valvular lesions. Serotonin is thought to be inactivated as it passes 
through lung parenchyma (30). Involvement of left sided valves is thought to be due 
to the presence of a patent foramen ovale with a right to left shunt, bronchial 
carcinoid or high levels of circulating vasoactive substances. 
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Figure 1.1 Carcinoid Involvement of Tricuspid Valve (TV) A. Right ventricular 
inflow view. Fixed, retracted and thickening of tricuspid valve leaflets and associated 
chordae. B. Continuous wave Doppler showing “dagger shaped” profile of tricuspid 
regurgitation (TR). C. Apical 4 chamber view showing dilated right ventricle with 
tricuspid valve leaflets failing to co-apt resulting in constant “semi-open” position. D. 
Colour Doppler demonstrating severe tricuspid regurgitation into a dilated right 
atrium. 
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Figure 1.2 Carcinoid Involvement of Pulmonary Valve (PV) A.  Right ventricular 
outflow tract. Thickened, fixed and retracted pulmonary valve leaflets that do not co-
apt. B. Continuous Wave Doppler of pulmonary valve  shows pulmonary 
regurgitation (PR) with short deceleration time and  pulmonary stenosis (PS). C. 
Parasternal short axis view of pulmonary valve. Shortened and retracted valve 
leaflets. D. Colour Doppler in diastole demonstrates turbulent pulmonary regurgitant 
flow. 
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 Small pericardial effusions are present in up to 10% of cases.  Myocardial 
metastases are rare. The Mayo clinic reviewed the echocardiograms of patients 
diagnosed with metastatic carcinoid tumour to the heart (31). 11 patients were found 
to have cardiac metastases. In 8 patients the metastases could be identified on 
echocardiography. In five patients the metastases were only identified at autopsy. 
Metastases were found in the right ventricle in 40% of cases, left ventricle in 53% of 
cases and ventricular septum in 7% of cases.  In the five patients with cardiac 
metastases found at autopsy but not seen with echocardiography the mean size was 
0.35cm. The mean size of metastases identified by echocardiography was 
2.4cm.This suggest that echocardiography is not able to detect small metastases.  
 Where transthoracic echocardiography cannot adequately visualise structures 
transoesophageal echocardiography should be undertaken (32).  Over the past 
decade there have been significant advances in echocardiography, including the 
development of three dimensional transoesophageal and transthoracic 
echocardiography. These new technologies have not been evaluated in the 
assessment of carcinoid heart disease. 
 
1.6.3 CARDIAC MAGNETIC RESONANCE IMAGING/ 64 SLICE COMPUTED TOMOGRAPHY 
 
  Cardiac magnetic resonance imaging has been shown to provide clear 
anatomic and functional information of both pulmonary and tricuspid valve in 
carcinoid heart disease. This can be of use, particularly in evaluating the pulmonary 
valve when it is difficult to visualise by echocardiography and limited ultrasound 
acoustic windows provide sparse echocardiographic data (33,34). Recently, 64 slice 
computed tomography coronary angiography has demonstrated similar anatomical 
32 
 
information (34). However the use of both modalities has been limited to isolated 
case reports. 
 
1.7 MANAGEMENT  
 
  Without intervention patients with carcinoid heart disease patients may 
develop progressively worsening symptomatic right heart failure. Life expectancy is 
significantly reduced. The Mayo clinic showed a mean life expectancy of 1.6 years 
for those with cardiac disease compared to 4.6 years for those without  cardiac 
disease in patients with metastatic midgut carcinoid tumours (5). Recent 
improvements in medical as well as surgical therapy, over the past decade, may 
have improved prognosis. 
 
1.7.1 MEDICAL THERAPY 
 
 Treatment of carcinoid disease rarely achieves cure. However with modern 
anti-tumour therapy progression can be substantially slowed. Many patients survive 
for many years after resection of a primary carcinoid tumour or palliative treatment of 
metastatic disease. Therefore cardiac intervention should be considered in order to 
offer symptomatic palliation .   
  Medical management consists of  relieving symptoms of right heart failure 
with a combination of loop and thiazide diuretic therapy. The use of digoxin may 
have a role to play but no convincing data for the right ventricle is available. 
Intuitively, optimising somatostatin analogue therapy should reduce circulating 
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vasoactive substances, reduce carcinoid syndrome and therefore may stabilise 
valvular lesions. 
 In patients not suitable for cardiac valve surgery the use of balloon 
valvuloplasty has been reported (35,36,37). Identification of suitable patients, with 
predominately stenotic valvular lesions, will be problematic as the majority of patients 
with CHD also have significant valvular regurgitation. Success of the procedure has 
been very limited. Although a couple of reports have shown some functional and 
haemodynamic benefit (36,37) others have noted either a lack of symptomatic 
benefit or a rapid relapse of symptoms and valvular stenosis where initial benefit did 
occur (35). 
 
1.7.2 SURGICAL THERAPY 
 
 Cardiac surgery offers definitive therapy for symptoms. Data has been limited 
to small, retrospective US series. In a study of 26 patients with symptomatic 
carcinoid heart disease, Connolly and colleagues noted marked symptomatic 
improvement, of greater than one NYHA class, occurred post valve replacement for 
carcinoid heart disease. This was confirmed in a later series detailing the results of 
11 patients undergoing surgery for left sided disease in addition to right sided 
valvular lesions. (29,38). Several series report high 30 day peri-operative mortality 
(38,39,40)    In a limited database review of 8 patients undergoing tricuspid valve 
replacement at Duke Medical Center 5 patients (63%) died within 30 days (40). The 
results of a larger cohort series from the Mayo Clinic has noted a fall in peri-
operative risk in their institution from over 20% in the 1980‟s to below 10% more 
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recently (41). The main peri-operative complications are bleeding and right 
ventricular failure. 
 In patients with pulmonary valve disease a small series has examined the 
effect of pulmonary valve replacement compared to pulmonary valvectomy. Connolly 
and colleagues compared the pre and post operative right ventricular diameter and 
function in 12 patients who underwent tricuspid and  pulmonary valve replacement to 
10 patients who underwent tricuspid valve replacement and pulmonary valvectomy, 
Right ventricular size decreased significantly post surgery in patients who underwent 
pulmonary valve replacement  compared to patients with pulmonary valvectomy. 
Right ventricular dysfunction did not recover post operatively in either group (42). 
The optimal timing of surgery in relation to severity of valve dysfunction and 
symptoms has not been identified. However based on this data, cardiac surgery at 
the onset of either symptoms or right ventricular dysfunction, with pulmonary valve 
replacement in addition to replacement of the tricuspid valve, may be considered 
prudent.  
 More controversial is the choice of valve prostheses. There are no large 
series comparing the choice of valve prosthesis. Initial reports favoured the use of 
mechanical prosthesis based on the assumption of damage to a bioprosthetic valve 
with vasoactive substances. There have been several case reports of bioprosthetic 
valve degeneration (43,44,45). Carcinoid plaques have caused pulmonary valve 
allograft failure as early as three months after implantation (44) and tricuspid 
biological graft dysfunction after as little as four years (45). However the advent of 
somatostatin analogues and other anti –tumour therapies may theoretically protect 
the valve from deposition of further carcinoid plaques.  Tissue valves have the 
advantage of not requiring anti-coagulation and consequently lower the risk of 
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bleeding in patients with hepatic dysfunction, reduce the risk of valve thrombosis 
(mechanical valve thrombosis is 4% per year) (46) and allows further procedures 
such as hepatic dearterilization to proceed at a later date. Therefore choice of 
prosthesis should be tailored to individual patient risk of bleeding, life expectancy 
and future interventions. 
 There have been several reports of patients presenting with  dyspnoea and 
hypoxia and cyanosis. Inter-atrial shunts via patent foramen ovale associated with 
valvular disease were described.  Surgical closure of a patent foramen ovale  and  
percutaneous transcatheter  closure devices in patients at high surgical risk  have 
produced dramatic  relief of symptoms (47,48) . Elevated right atrial pressure 
secondary to valvular disease may have contributed to   stretching of the foramen 
ovale and development of a right to left shunt. 
 
1.7.3 PERI-OPERATIVE ANAESTHETIC MANAGEMENT 
 
 Carcinoid crises characterised by hypotension, bronchospasm and flushing 
can be precipitated by surgery as well as drugs that release catecholamine and 
histamines.  During the peri-operative period it can be difficult to differentiate 
between carcinoid crisis and hypotension secondary to myocardial dysfunction.  
Peri-operative octreotide, aimed at reducing serotonin release, is the most 
efficacious treatment for preventing crises during surgery and is the mainstay 
treatment of carcinoid crisis (49,50). Intravenous octreotide (50 – 100 micrograms 
per hour) should be started at least two hours prior to surgery. The infusion should 
continue for forty-eight hours post surgery. Patients may then require subcutaneous 
octreotide depending on previous somatostatin analogue requirements and current 
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control of carcinoid syndrome. Avoidance or minimising use of drugs known to 
precipitate mediator release such as opioids, the neuromuscular relaxants 
atracurioum and catecholamine producers such as dopamine and epinephrine, may 
reduce the risk of carcinoid crisis (50,51). 
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AIMS AND OBJECTIVES: 
 
 The aim of my thesis is to characterise the clinical manifestations of carcinoid 
heart disease. This will include 5 main areas of investigation: 
 
1. Determine the prevalence and clinical features of carcinoid heart disease in a 
European cohort of patients in a contemporary era of medical management. 
 
2. Determine the utility of biomarkers including N-Terminal pro Brain Natriuretic 
Peptide in the diagnosis of carcinoid heart disease. 
 
3. Identify the echocardiographic features (including two and three dimensional 
imaging) of carcinoid heart disease. 
 
4. Identify risk factors for the development and progression of carcinoid heart 
disease. 
 
5. Investigate the role of cardiac surgery in the management of patients with 
carcinoid heart disease. 
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Chapter 2: Prevalence and Clinical Features of Carcinoid Heart 
Disease 
 
2.1 Introduction 
 
2.2  Methods 
2.2.1  Patient Group 
2.2.2  Echocardiography 
2.2.3  Biochemical Markers 
2.2.4  Functional Status 
2.2.5  Statistical Analysis 
 
2.3 Results 
 
2.4 Discussion 
 
2.5 Conclusion 
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2.1 INTRODUCTION 
 
Carcinoid heart disease  has been reported to develop in up to 70% of  
patients with carcinoid syndrome (5,6). Over the past two decades, new anti-tumour 
therapies for carcinoid syndrome including somatostatin analogues, interferon and 
targeted radionuclide therapy have emerged (2). These treatments result in inhibition 
of  the production of  tumour metabolites and may thereby alter  the development 
and prevalence of carcinoid heart disease. Echocardiography remains the gold 
standard for diagnosis of carcinoid heart disease. Currently, in carcinoid patients, 
echocardiography is generally performed only if there is a clinical suspicion of 
valvular pathology due to symptoms or clinical signs. We aimed to establish the 
prevalence of carcinoid heart disease in an era of new treatment modalities and 
explore whether a screening programme needs to be established.                                                      
 
2.2 METHODS 
 
2.21 Patient Group 
 
One hundred and fifty consecutive patients with histologically confirmed 
carcinoid tumours of midgut origin and who had carcinoid syndrome were 
prospectively enrolled from April 2006. The Neuroendocrine Tumour Unit at the 
Royal Free Hospital is a large, tertiary referral centre for the management of 
neuroendocrine tumours. The Unit has more than 800 neuroendocrine tumour 
patients under active follow up. Ethical approval was obtained from the Royal Free 
Hospital Ethics Committee. Informed consent was obtained from all participants.  
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Diagnosis of carcinoid  was based on histological examination of either 
primary tumour or liver metastases biopsy. Histology graded the tumour as high or 
low grade depending on differentiation and Ki-67 proliferation index. 
Demographic data collected included information on patient age, sex, location 
of  carcinoid tumour, tumour grade, duration of diagnosis of carcinoid tumour, current 
and previous anti-tumour therapies including treatment with somatostatin analogue. 
 
2.2.2 Echocardiography 
 
Comprehensive two dimensional transthoracic echocardiography was 
performed using Siemens Sequioa 512 (Siemens, USA). The echocardiogram was 
reviewed by 2 cardiologists blind to the clinical data. Multiple views of each cardiac 
valve were obtained. 
 The pulmonary valve was visualised from the high parasternal, long axis view 
of the right ventricular outflow tract and the parasternal short axis view. The tricuspid 
valve was visualised from the low parasternal long axis view of right ventricular 
inflow tract, short axis and apical four chamber views.  The aortic and mitral valves 
were assessed from parasternal  long axis, apical four, three and two chamber 
views.  
Valvular regurgitation was assessed and graded  according to The American 
Society of Echocardiography  guidelines (52) . Valve stenosis was quantified 
according American College of Cardiology Guidelines (53). Pulmonary stenosis 
(peak gradient across valve)was graded as mild (<25mmHg), moderate (25-
50mmHg) or severe(>50mmHg). Tricuspid stenosis (mean gradient across valve) 
was graded  as  mild (2- 5mmHg), moderate (5- 8mmHg) or severe(>8mmHg). 
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 Contrast echocardiography was performed on all patients. 9mls of agitated 
saline was mixed with 0.5ml of the patients venous blood and 0.3mls of air. Boluses 
of 5mls of the agitated mixture were injected via a 20 gauge cannula inserted into a 
large vein in the left ante-cubital fossa. Cough and Valsalva manoeuvre were 
performed after introduction of the contrast. Either sub-costal, parasternal short axis 
or apical 4 chamber views were used depending on optimal visualisation of the atria. 
Carcinoid heart disease was defined as the presence of characteristic 
thickening, reduced excursion or retraction of valvular leaflets (with associated 
evidence of valvular stenosis or regurgitation), or the presence of myocardial 
metastases, in the absence of other aetiologies. The presence of patent foramen 
ovale was defined as the passage of micro-bubbles from right atrium into the left 
atrium within 3 cardiac cycles of contrast visualisation in right atrium. 
 
2.2.3 Biochemical Parameters 
 
Twenty-four hour urine 5-HIAA samples were collected  in bottles containing 
acetic acid. Samples were evaluated using reversed phase high performance liquid 
chromotography assay. Cg A samples were taken from antecubital fossa in a serum 
gel tube. Cg A was measured using DAKO Chromogranin A Enzyme-linked 
immunosorbent assay (DAKO A/S, Glostrup, Denmark). 
 
2.2.4 Functional Status 
 
Patients functional status was graded using NYHA classification. All patients 
had full examination of the cardiovascular system by a trained cardiologist.  
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2.2.5 Statistical Analysis 
 
 Comparison between continuous variables was measured using Mann-
Whitney U Test and comparison between categorical variables was measured using 
the Chi Square Test or Fisher exact test where the number of variables was less 
than five. A value of P < 0.05 was considered to be of statistical significance. 
Analysis was undertaken using SPSS version 14, statistical software (SPSS, 
Chicago,USA). 
 
2.3 RESULTS 
 
One hundred and fifty patients were enrolled over the study period. No patient 
was excluded. Thirty (20%) patients with carcinoid syndrome were found to have 
carcinoid heart disease. There was no significant difference in age, sex, presence of 
liver metastases or tumour grade between those with carcinoid heart disease and 
those without carcinoid heart disease. The majority of patients in both groups were 
receiving somatostatin analogues. Very few patients received interferon therapy and 
no patient received a combination of somatostatin analogue and interferon therapy. 
There were significantly higher levels of  Cg A and urinary 5-HIAA in the group with 
carcinoid heart disease compared to the group without carcinoid heart disease, 
p<0.0001 (table 2.1).   
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Table 2.1 Baseline characteristics of  patients. 
 
Variable Carcinoid Heart Disease P value 
Present 
N=30 
Absent 
N=120 
Age (Years) 65(22-
86) 
65(30-87) 0.72 
Sex (Female) 14 (47%) 55(46%) 0.93 
Newly Diagnosed Patients 6(20%) 29(24%) 0.81 
Time from diagnosis of carcinoid tumour (Years) 5(1-16) 4.5(0.4-20) 0.87 
Presence of liver metastases 29(97%) 102(85%) 0.12 
Therapy Somatostatin Analogue 
Duration of Therapy (Months) 
22 (73%) 
27(13.5-
40) 
86 (72%) 
24(12-40) 
0.86 
0.87 
Chemotherapy 0 (0%) 8 (7%) 0.16 
Targeted Radionuclide 6 (20%) 16 (13%) 0.25 
Interferon 
Duration of Therapy (Months) 
0 (0%) 
0 
7 (6%) 
4.5(3-12) 
0.32 
N/A 
123
I-metaiodobenzylguanidine 5 (3%) 15 (13%) 0.37 
Surgical Resection 14(47%) 70(58%) 0.25 
Tumour 
Grade 
Intermediate 2(7%) 5 (4%) 0.43 
Low 28(93%) 115 (96%) 0.43 
Chromogranin A (pmol/L) 1000(56-
1000) 
238(37-1000) <0.0001 
Peak 5-hydroxyindolacetic acid  (µMol/24 hours) 880(111-
2228) 
0 (0 -200) <0.0001 
Micromoles (uMol), picomoles per litre (pMol/L). Not applicable (N/A). Age is 
presented as mean and standard deviation. Chromogranin A, Urine 5-
Hydroxyindolacetic acid  and duration of carcinoid tumour and therapy are 
represented by median and interquartile range.     
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The majority of patients with carcinoid heart disease (53%, 16 patients)had 
only right sided valvular involvement. Fourteen (47%) of those with carcinoid heart 
disease were found to have both left and right sided valvular dysfunction. 
Of those with only right sided carcinoid heart disease, isolated tricuspid valve 
lesions were most common in 9 (56%) cases and isolated pulmonary lesions were 
rare being present in 2 (13%) cases. Both pulmonary and tricuspid  valve 
involvement was present in 5(31%)  cases. Abnormalities of the tricuspid valve most 
commonly manifest as regurgitation of moderate to severe grade. Pulmonary 
valvular abnormalities manifest as regurgitation and stenosis of mild to moderate 
severity (table 2.2).  
 
Table 2.2 Carcinoid Heart Disease – Functional Valvular Abnormalities 
Echocardiographic 
Characteristic 
Number Echocardiographic 
Characteristic 
Number  
Tricuspid 
Stenosis 
None 17(57%) Tricuspid 
Regurgitation 
None 3(10%) 
Mild 9 (30%) Mild 5(17%) 
Moderate 4(13%) Moderate 7(23%) 
Severe 0(0%) Severe 15(50%) 
Pulmonary 
Stenosis 
None 16(53%) Pulmonary 
Regurgitation 
None 15(50%) 
Mild 8(27%) Mild 10(33%) 
Moderate 6(20%) Moderate 5(17%) 
Severe 1(3%) Severe 0(0%) 
Mitral 
Regurgitation 
None 18(60%) Aortic 
Regurgitation 
None 21(70%) 
Mild 7(23%) Mild 6(20%) 
Moderate 5(17%) Moderate 3(10%) 
Severe 0(0%) Severe 0(0%) 
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Of the left sided carcinoid heart disease, the mitral valve was most commonly 
involved in 5(36%) patients and the aortic valve was involved in  2 (14%) patients. 
Both aortic and mitral valves were involved in 7 (50 %) cases of left sided carcinoid 
heart disease. All patients with left sided carcinoid heart disease had a patent 
foramen ovale. Valvular regurgitation  of mainly mild to moderate severity was seen. 
None of the patients had valvular stenosis (table 2.2). 
Thirteen (43%) of the patients with carcinoid heart disease were in NYHA  
Class I. Twelve (40%), four (13%) and one (3%) of the patients with carcinoid heart 
disease were in functional NYHA classes II, III and IV respectively . Overall 17 
patients (57%) with moderate to severe tricuspid regurgitation were in NYHA class I 
– II (table 2.3).  
 
Table 2.3 Severity Of Tricuspid Regurgitation In Relation To New York Heart 
Association Class 
New York Heart 
Association Class 
Severity of Tricuspid Regurgitation 
None/Trivial Mild Moderate Severe 
I 2 (7%)  3 (10%) 5 (17%) 3 (10%) 
II 1 (3%) 2 (7%) 2 (7%) 7 (23%) 
III 0 (0%) 0 (0%) 0 (0%) 4 (13%) 
IV 0 (0%) 0 (0%) 0 (0%) 1 (3%) 
 
 
Eleven (37%) of the  patients with carcinoid heart disease had no clinical 
signs of cardiac abnormalities on physical examination. 10 (33%) did not have  
raised jugular venous pressure, 15(50%) did not have a cardiac murmur and 8(27%) 
did not have ankle oedema. 
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2.4 DISCUSSION 
 
 The prevalence of carcinoid heart disease in this study (20%) is lower than 
that reported in previous decades (50 – 70%) (5,6). There may be several reasons 
for the differences reported. Previous studies may be subject to referral bias as they 
included patient referred for echocardiography due to a clinical suspicion of carcinoid 
heart disease rather than screening all patients with carcinoid syndrome. Secondly, 
the characteristics of patients seen at different institutions may differ. Thirdly, over 
the past decade new anti-tumour therapies which have been shown to cause 
significant reduction in the production of  tumour metabolites have been introduced. 
Most notable of these therapies are somatostatin analogues. These analogues 
control symptoms of carcinoid syndrome and also result in a reduction of 5-HIAA, a 
urinary metabolite of serotonin, in up to 70% of patients (54).  
In our cohort of patients the majority of carcinoid patients were receiving 
somatostatin analogues. In our group with carcinoid heart disease, the majority were 
also receiving somatostatin analogues yet had significantly higher urinary 5-HIAA 
and Cg A levels than the group without carcinoid heart disease. This may represent 
a lack of biological and biochemical response to these analogues. 5-HT is thought to 
be important in the pathogenesis and progression of carcinoid heart disease having 
a high sensitivity although low specificity (19,20). Therefore further research to 
delineate whether aggressive medical therapy with higher dose or higher affinity 
somatostatin analogues to prevent the development of carcinoid heart disease is 
needed. 
 Pellikka et al (5) reported 90% of tricuspid regurgitation being of moderate to 
severe degree. In our study only 73% of tricuspid regurgitation was of moderate to 
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severe degree and 27% was of trivial or mild degree. The higher incidence of mild  
valvular involvement in our cohort may be in part due to the prospective nature of 
this study allowing diagnosis of early disease in asymptomatic individuals and 
significant advances in  echocardiography techniques over the past two decades  
may have allowed better visualisation of valves and quantification of valvular 
regurgitation. 
A substantial proportion of patients with carcinoid heart disease are 
asymptomatic. This group included a spectrum of severe to mild disease. Patients 
with early stage disease and mild functional valvular abnormalities would be 
expected to have little by signs or symptoms. However it is important to diagnose  
early stage  disease as an early diagnosis would allow monitoring and potentially a 
chance to retard progression of their carcinoid heart disease by reduction of 
circulating 5-HT levels. It is equally important to diagnose asymptomatic but 
advanced carcinoid heart disease (57% of our patients) as it will allow timely surgical 
intervention prior to the development of right ventricular failure. 
A substantial proportion of patients did not display signs of valvular disease. 
This is not surprising as previous studies have shown auscultatory  and clinical 
examination is not an accurate predictor of the presence of tricuspid regurgitation 
(55). Our results differ from previous reports where the majority of patients with 
carcinoid heart disease had cardiac murmurs present (5,56). Whereas these studies 
included patients referred for echocardiography or with clinical suspicion of carcinoid 
heart disease our study prospectively screened consecutive patients with carcinoid  
syndrome regardless of clinical suspicion. Secondly, in our cohort the proportion of 
patients with mild involvement of valvular structures is greater than previously stated. 
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Intuitively auscultation would be less likely to detect cardiac murmurs in these 
patients. 
Including only new referrals with a diagnosis of carcinoid will not establish the 
true incidence of carcinoid heart disease as a  substantial proportion of  patients will 
have had a carcinoid tumour for several years before a diagnosis is made and 
autopsy studies of carcinoid tumours show many are never diagnosed whilst alive 
even though they may have had symptoms of carcinoid syndrome. Therefore we 
decided to screen our  patient population. This would indicate the total number of 
patients with carcinoid heart disease representing the prevalence and burden of 
disease in the patient group.  
 
CONCLUSION 
In conclusion the prevalence of carcinoid has reduced from previous decades. 
This is likely to be due to the introduction of modern anti-tumour therapies. A 
screening programme for carcinoid heart disease in this patient group is warranted  
as a substantial number of patients are functionally asymptomatic and do not have 
signs of carcinoid heart disease. 
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3.1 INTRODUCTION 
 
Carcinoid heart disease is characterised by the deposition of fibrotic plaques 
on endocardial surfaces of the heart, resulting in the development of a complex 
combination of predominantly right-sided valvular lesions (5). Many patients are 
initially asymptomatic despite severe disease. Early detection and timely intervention 
is essential as development of right ventricular dysfunction heralds a poorer 
prognosis and does not recover post cardiac valve replacement (29,42) . 
Patients with carcinoid syndrome are already subject to an intensive regimen 
of investigations and therapies necessary for monitoring and treatment of their 
tumour.  Within this setting, routine echocardiography for the detection of carcinoid 
heart disease may be time- consuming and expensive .  
BNP are neurohormones released by the ventricle in response to an increase 
in ventricular wall stress due to both volume and pressure overload (58,59,60). BNP 
is synthesised as a pre-hormone (proBNP) comprising 108 amino acids. Upon 
release into the circulation, it is cleaved in equal proportions into the biologically 
active 32 amino acid BNP, which represents the C-terminal fragment, and the 
biologically inactive 76 amino acid N-terminal fragment (NT-proBNP).  BNP is stable 
in whole blood at room temperature for 24 hours, whereas NT-proBNP is stable for 
at least 72 hours.  We sought to investigate whether NT-proBNP could be used as a 
biomarker of the presence of carcinoid heart disease and thereby be used to select 
which patients should be further evaluated by echocardiography.   
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3.2 METHODS 
 
3.2.1 PATIENT GROUP 
 
Two hundred and four patients diagnosed with carcinoid tumours of midgut 
origin and a history of carcinoid syndrome were consecutively and prospectively 
enrolled from April 2006.  
Diagnosis of carcinoid  was based on histological examination of either 
primary tumour or liver metastases biopsy. Histology graded the tumour as high or 
low grade depending on differentiation and Ki-67 proliferation index. 
 The following demographic data was collected: age, sex, duration of 
carcinoid symptoms, duration of diagnosis of carcinoid tumour and the  presence of 
liver metastases. The functional status of patients was assessed by NYHA Class.  
All patients underwent comprehensive two-dimensional echocardiography. 
Blood samples for NT-proBNP, Cg A, serum creatinine and a 24 hour urinary sample 
for 5-HIAA were collected. 
Patients were excluded from the study if suitable echocardiographic windows 
to allow adequate visualisation of cardiac structures were not obtainable or if 
creatinine clearance was less than 60 millilitres per minute.  
 The study was approved by the ethical review committee of the institution 
and all patients gave written informed consent. 
 
3.2.2 Echocardiography 
Two dimensional transthoracic echocardiography was performed using  
Acuson Sequoia C512 (Siemens Medical Systems, USA). All studies were reported 
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by two cardiologists blinded to patient‟s symptom status, clinical and biochemical 
data.  
Diagnosis of carcinoid heart disease was based on echocardiographic criteria. 
Carcinoid heart disease was defined as the presence of characteristic thickening, 
reduced excursion or retraction of valvular leaflets (with associated evidence of 
valvular stenosis or regurgitation), or the presence of myocardial metastases, in the 
absence of other aetiologies. Left sided CHD was only diagnosed in the presence of 
right sided CHD. 
 Echocardiograms of patients diagnosed with carcinoid heart disease were 
scored in order to obtain an objective description of the severity of carcinoid heart 
disease. Each affected valve was scored individually (table 3.1). The total score of all 
affected valves and the right ventricle assessment was combined to produce a final 
score. The score will assess valve leaflet thickness, mobility, shortening/retraction 
and ability to co-apt together with the degree of regurgitation or stenosis and 
ventricular dilatation and function.  
Table 3.1 Valvular Abnormalities Score 
 
 
 
Twenty-five percent of patients found to have carcinoid heart disease were 
scored by two readers to assess inter-observer variability. 
Valve morphology and function was evaluated in several views. Pulmonary 
valve was visualised from high parasternal, long axis view of right ventricular outflow 
 Score 
 0 1 2 3 
Leaflet Thickness < 3mm 3-4mm 4-5mm >5 mm 
Leaflet Mobility Normal Leaflet 
excursion  
<75% of normal 
Leaflet 
excursion <50% 
of normal 
Leaflet 
excursion  
<25% of normal 
or fixed 
Leaflet Retraction Normal Mild Moderate Severe 
Valve Stenosis Normal Mild Moderate Severe 
Valve Regurgitation Normal Mild Moderate Severe 
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tract and parasternal short axis view. Tricuspid valve was visualised from low 
parasternal long axis view of right ventricular inflow tract, short axis and apical four 
chamber view. Aortic and mitral valves were assessed from parasternal long axis, 
short axis, apical four, three and two chamber views. Valve regurgitation severity and 
quantification were assessed and graded according to The American Society of 
Echocardiography  guidelines (52). Valve stenosis was quantified according 
American College of Cardiology Guidelines (53). Pulmonary stenosis was graded 
(according to peak gradient across valve) as mild (<25mmHG), moderate (25-
50mmHg) or severe(>50mmHG).Tricuspid stenosis was graded (mean gradient 
across valve)  as  mild (2 -5mmHg), moderate ( 5- 8mmHg) or severe(>8mmHg). 
 Right and left ventricular function and sizes were assessed and calculated 
according to American Society of Echocardiography guidelines. Right ventricular 
function was measured using right ventricular fractional shortening change. The right 
ventricular diameter was measured in the apical four chamber view at the level of 
tricuspid valve leaflet tips in diastole. Left ventricular ejection fraction was calculated 
by the modified Simpson‟s method from apical four and two chamber views (61).    
 
3.2.3 Biochemical Markers 
 
NT-proBNP samples were taken, immediately prior to echocardiography, from 
the left antecubital fossa at room temperature in a serum gel tubes. Analysis was 
undertaken immediately, after being centrifuged, by Roche Modular Analytics E-170 
immunoassay analyser using electrochemilunescence detection. 24 hour urine 5-
HIAA samples were collected in bottles containing acetic acid. Samples were 
evaluated using reversed phase high performance liquid chromatography assay. Cg 
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A samples were taken from antecubital fossa in a serum gel tube. CgA was 
measured using DAKO Chromogranin A Enzyme-linked immunosorbent assay 
(DAKO A/S, Glostrup, Denmark). Creatinine clearance was calculated from the 
Cockcroft-Gault Formula. 
 
3.2.4 Statistical Analysis 
 
 The Mann-Whitney U test was used to compare differences between 
continuous variables. The Chi squared test was used to compare categorical 
variables. When the number of categorical variables was less than five the Fisher 
exact test was used. Kruskal Wallis Test was used to compare differences in NT-
proBNP levels of subjects grouped according to NYHA class. Receiver operating 
characteristic plot analysis was used to determine the sensitivity and specificity of 
NT-proBNP for diagnosis of carcinoid heart disease.  The cut-off for NT-proBNP was 
determined retrospectively by ROC coordinated for a maximum sensitivity of > 90% 
and minimal loss of specificity. Spearman Rank Correlation Co-efficient (r) was used 
to compare the association of NT-proBNP level to carcinoid heart disease score. 
Inter-observer concordance was expressed as exact agreement and by the Kappa 
(κ) statistic. Poor agreement was indicated by a κ value of <0.2, fair agreement 
indicated by a κ value of 0.21 – 0.4, moderate agreement was indicated by a κ value 
of 0.41 - 0.6, good agreement was indicated by a κ value 0.61 – 0.8 and excellent 
agreement by a κ value > 0.81.The number of patients screened with 
echocardiography needed to diagnose one case of carcinoid heart disease was 
defined as the ratio of the total number of patients to the number of patients with 
echocardiograms confirming carcinoid heart disease. A P-value of <0.05 was 
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considered statistically significant. Statistical analysis was performed using 
StatsDirect Version 2.5.7 (StatsDirect, United Kingdom).  
 
3.3 RESULTS 
Two hundred and four patients were enrolled in the study. After initial 
assessment four patients were excluded; suitable echocardiographic windows were 
not obtainable in one patient and in three patients creatinine clearance was below 
the entry criteria. Two hundred patients were included in the analysis.  
Carcinoid heart disease was present in  39 (19.5%) of  patients. There was no 
significant difference in age, sex, duration of carcinoid tumour, presence of liver 
metastases or tumour grade between those with or without carcinoid heart disease. 
There were significantly greater levels of Cg A and urinary 5-HIAA in the carcinoid 
heart disease group compared to the group without carcinoid heart disease. This, as 
might be expected, probably represents greater disease activity and tumour burden 
in the group with carcinoid heart disease (table 3.2). The sensitivity and specificity of  
urinary 5-HIAA for a diagnosis of carcinoid heart disease at a cut-off level of 
57µmol/24 hours was 0.93 and 0.52 respectively. 
Median NT-proBNP was significantly higher in those with carcinoid heart 
disease (median 1149pg/ml (interquartile range 404 - 1601)) than in those without 
(median 101pg/ml (interquartile range 50 – 169)), p<0.001. The sensitivity and 
specificity for carcinoid heart disease, at a cut-off level of 260pg/ml, was 0.92 (92%) 
and 0.91 (91%) respectively. Area under receiver operator curve was 0.96 (95% 
Confidence Interval 0.93 – 0.98). The negative and positive predictive value were 
0.98 and 0.71 respectively (figure 3.1).   
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Table 3.2 Baseline characteristics 
 Carcinoid Heart 
Disease (n=39) 
No Carcinoid 
Heart Disease 
(n=161) 
P value 
Age 63 ± 12.2 65 ± 11.0 0.39 
Sex (Females) 18 (46%) 78 (48%) 0.93 
Duration of carcinoid tumour (years) 4 (2 - 5.5) 5 (3 -7) 0.40 
Presence of liver metastases 37 (95%) 130 (81%) 0.06 
Therapy Somatostatin Analogue 31(80%) 120(75%) 0.67 
Interferon 1(3%) 8(5%) 0.99 
123
I-
metaiodobenzylguanidine 
6(15%) 23(14%) 0.80 
Targeted Radionuclide 10(26%) 22(14%) 0.11 
Chemotherapy 1(3%) 10(1%) 0.70 
Surgical Resection 19(49%) 96(60%) 0.29 
Tumour Grade Medium 2 (5%) 6(4%) 0.66 
Low 37 (95%) 155(96%) 0.66 
Cg A (pmol/L) 1000 (928-1000) 224(62-561) <0.0001 
Peak 5-HIAA ( µMol / 24 hours ) 880 (458-1659) 25(0-217) <0.0001 
NYHA  I 16(41%) 96 (60%) 0.05 
II 15(38%) 55(34%) 0.71 
III 6(15%) 10(6%) 0.09 
IV 2(5%) 0(0%) 0.04 
  
Chromogranin A (Cg A), 24 hour urinary 5-hydroxyindolacetic acid (5-HIAA), New 
York Heart Association Functional Class (NHYA), Picomoles per litre (pMol/L), 
Micromoles (uMol) Entries are number (%). Mean and standard deviation is used for 
age. Median and interquartile range is used for  duration of carcinoid tumour, Cg A 
and 24 hour urinary 5-HIAA.   
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Figure 3.1 Receiver Operator Curve of N Terminal Brain Natriuretic Peptide (NT-
proBNP) for diagnosis of Carcinoid Heart Disease. 
  
Median Carcinoid Score for those with carcinoid heart disease was  18 
(interquartile range 11 to 26). Left ventricular function was preserved in all patients. 
The range of functional valvular abnormalities is described in table 3.3 . The score 
correlated positively with NT-proBNP. Spearman Rank Correlation co-efficient (r) 
was 0.81 (95% confidence interval 0.67 - 0.89), p<0.0001 (figure 3.2).  
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Table 3.3 Echocardiographic Features of Carcinoid Heart Disease 
Echocardiographic 
Characteristic 
Number(%) Echocardiographic 
Characteristic 
Number %) 
Tricuspid 
Stenosis 
None 24(62%) Tricuspid 
Regurgitation 
None 3(8%) 
Mild 11(28%) Mild 6(15%) 
Moderate 4(10%) Moderate 9(23%) 
Severe 0(0%) Severe 21(54%) 
Pulmonary 
Stenosis 
None 20(51%) Pulmonary 
Regurgitation 
None 18(46%) 
Mild 10(26%) Mild 15(38%) 
Moderate 8(21%) Moderate 6(15%) 
Severe 1(3%) Severe 0(0%) 
Mitral 
Regurgitation 
None 26(67%) Aortic 
Regurgitation 
None 25(64%) 
Mild 9(23%) Mild 9(23%) 
Moderate 4(10%) Moderate 4(10%) 
Severe 0(0%) Severe 1(3%) 
Mitral Stenosis None 39(100%) Aortic Stenosis None 39(100%) 
RV Diameter Diastole (cm) 3.9 ( 3.5 – 4.1 ) 
Right Atrial Area (cm
2
) 19.8 ( 16.2  - 24.8 ) 
Left Ventricle Ejection 
Fraction (%) 
62% ( ±6.2) 
Right 
Ventricular Function 
Normal 
 
35 (90%) 
Mildly Reduced 
 
3 (8%) 
Moderately 
Reduced 
1(3%) 
Severe 
Reduced 
0 (0%) 
 
Median and range are given for right atrial area and right ventricular diameter. Mean 
and standard deviation are given for left ventricular ejection fraction. 
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Figure 3.2 Correlation of  N Terminal Brain Natriuretic Peptide (NT-proBNP) and 
Carcinoid Heart Disease Score. 
 
Of the 10 studies scored by both readers, exact inter-observer agreement was 
present in 6(60%) of patients.  Three patients scores differed by 2 points and 1 
patients score differed by one point. A corresponding κ value of 0.89 confirmed 
overall excellent agreement. 
NT-proBNP was significantly related to symptomatic status increasing with 
higher functional NYHA class (Median NT-proBNP: NYHA Class I 304pg/ml, NYHA 
Class II 1271pg/ml, NYHA Class III 2783pg/ml, NYHA Class IV 4300pg/ml, P<0.001, 
figure  3.3).  
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Figure 3.3 Box plot  of N Terminal Brain Natriuretic Peptide (NT-proBNP) levels 
according to New York Heart Association (NYHA) functional class in patients with 
carcinoid heart disease. (The box defines interquartile range and median 
represented by crossbar. The error bars depict range). 
Of the 39 patients found to have echocardiographic evidence of carcinoid 
heart disease, 16 (41%) patients were functionally asymptomatic (NYHA Class I). 
Fourteen (88%) of these patients had an NT-proBNP level greater than the threshold 
of 260pg/ml.  
 NT-proBNP was elevated in 15 patients without echocardiographic 
evidence of carcinoid heart disease (false positives). Two patients were found to 
have aortic regurgitation, 3 patients had aortic stenosis, 2 patients had mitral 
regurgitation and left ventricular dysfunction was present in 8 patients. 
If patients with carcinoid tumours of mid-gut origin are screened for carcinoid 
heart disease using echocardiography alone 5.1 patients will need to be screened in 
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order to detect 1 patient with carcinoid heart disease. If NT-proBNP is used as a 
screening test and only those with a level of greater than 260pg/ml underwent 
echocardiography 1.4 patients will need to undergo echocardiography in order to 
detect 1 patient with carcinoid heart disease.  
 
3.5 DISCUSSION 
 
 This is the first large prospective trial to assess whether NT-proBNP can be 
used as a biomarker of the presence of carcinoid heart disease encompassing the 
full range of valvular abnormalities seen in this condition. Median NT-proBNP is 
significantly higher in patients with carcinoid heart disease than those patients 
without. The sensitivity and specificity of NT-proBNP at a cut-off value of 260pg/ml 
were 0.92 and 0.91 respectively. A high negative predictive value of 0.98, at this cut 
off level, may allow this biomarker to be used to exclude carcinoid heart disease. 
Secondly, the level of NT-proBNP correlates with the severity  of carcinoid heart 
disease (carcinoid heart score) and higher NYHA functional classes have greater 
median NT-proBNP levels than lower NYHA classes although there is overlap 
between the ranges. 
Currently, the incidence of carcinoid tumours is increasing. The overall 5 year 
survival for small bowel carcinoid tumours in the present decade is over 60% (3,57). 
The development of an array of modern anti-tumour therapies, most notably 
somatostatin analogues, over the past 2 decades has led to an increased ability to 
provide relief of the symptoms of carcinoid syndrome and stabilise carcinoid tumours 
(62,63,64). In this era, more emphasis will be placed on the detection and 
management of carcinoid heart disease where valve replacement can provide 
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considerable symptomatic relief of cardiac symptoms and may improve 
prognosis(38,41).   
Assessment, monitoring and management of this complex form of valvular 
heart disease requires expert and experienced assessment. The relative rarity of 
carcinoid heart disease may lead to assessment of these patients, by 
echocardiography, in centres that are not familiar particularly with the early changes 
of carcinoid heart disease. Secondly, evaluation by echocardiography, in addition to 
the intensive regimen of investigations and therapies already imposed on the 
carcinoid patient,   is expensive, time consuming and in some areas timely 
availability is limited. Thirdly, at present, screening for carcinoid heart disease is not 
routine and usually only occurs when clinical suspicion exists. A large proportion of 
our patients were functionally asymptomatic despite the presence of  carcinoid heart 
disease. A biomarker which is not operator dependent, quick, reliable and relatively 
inexpensive would be advantageous in order to identify and select patients who may 
require further expert evaluation. 
 An early diagnosis of carcinoid heart disease is essential for management 
and therapy decisions regarding the carcinoid tumour itself and for timely cardiac 
surgical intervention prior to the development of right ventricular dysfunction. Right 
ventricular dysfunction may not recover post cardiac valve replacement, increases 
operative risk of cardiac surgery and leads to the development of signs and 
symptoms associated with right heart failure.  We have shown the use of NT-proBNP 
can be used as an accurate marker of the presence cardiac involvement.  This 
marker is able to detect both early stage disease and those with advanced disease 
and subsequent right ventricular dysfunction.   
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5-HT is an important factor in the pathogenesis and progression of carcinoid 
heart disease (17,19,20). Our results confirm urinary 5-HIAA has a high sensitivity 
but very low specificity for the development of carcinoid heart disease (17). 
Therefore it is not clinically useful as a screening tool.   
The present study does not provide sufficient evidence for the use of NT-
proBNP as a tool for monitoring progression of carcinoid heart disease. Further long 
term follow up studies combining serial echocardiograms and parallel measurements 
of NT-proBNP are required to evaluate whether NT-proBNP may provide a modality 
for monitoring patients with carcinoid heart disease.  
 The carcinoid score we developed was based on our experience of assessing 
and reviewing the echocardiograms of over 200 carcinoid patients. Some of the 
components of the score relied on semi-quantative assessments. This was because 
components such as degree of excursion of valve leaflets can be difficult to quantify. 
Despite this limitation, inter-observer agreement was good.  
The presence of left sided carcinoid heart disease could be difficult to 
distinguish from rheumatic or degenerative/age related valve disease. The 
characteristic features of left sided carcinoid heart disease include diffuse valve 
thickening with reduced excursion, retraction and valvular regurgitation. They do not 
include fusion of commissures or significant valvular stenosis characteristic of 
rheumatic disease. Secondly, the median age of the patient cohort is relatively young 
and the degree of valvular thickening seen is much greater than would be expected 
for age related changes.  Thirdly, left sided carcinoid heart disease was only 
included in the carcinoid score in the presence of right sided valvular lesions as 
isolated left sided carcinoid heart disease only occurs in the presence of primary 
bronchial carcinoid.  
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 There is intra-individual variation in NT-proBNP levels. Some studies have 
noted differences of up to 20% between readings (65,66).This is unlikely to make a 
difference to the diagnostic ability of NT-proBNP in the  majority of patients as they 
are either substantially  above or below the cut-off value.  This is most likely to be a 
problem in patients very near the cut-off level for carcinoid heart disease.  In the 
three patients with carcinoid heart disease but false negative NT-proBNP (below the 
cut-off level) the values were very close to 260pg/ml. These patients had very mild 
disease with little functional consequences. The possible options available to the 
clinician are either to perform echocardiography on all patients near the cut-off line or 
repeat the measurement in these patients at a later date.   
 
3.6 Conclusion 
 
In conclusion, NT-proBNP is an excellent biomarker of the presence and severity of 
carcinoid heart disease in patients with carcinoid syndrome. A high negative 
predictive value may allow its use as a screening test for carcinoid heart disease 
allowing a targeted approach  to the use of echocardiography and further expert 
evaluation in carcinoid heart disease. 
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Chapter 4. Features of Carcinoid Heart Disease Identified By Two- 
and Three- Dimensional Echocardiography and Cardiac Magnetic 
Resonance Imaging. 
 
4.1 Background 
4.2 Methods 
4.2.1 Patient Group 
4.2.2 Two Dimensional Echocardiography 
4.2.3 Three Dimensional Echocardiography 
4.2.4 Three Dimensional Transoesphageal Echocardiography 
4.2.5  Cardiac Magnetic Resonance Imaging 
4.2.6 Statistical Analysis 
4.3 Results 
4.3.1 Right Ventricle, Atrium and Tricuspid Valve 
4.3.2 Pulmonary Valve 
4.3.3 Left Sided Heart Valves and Foramen Ovale 
4.3.4 Aortic Valve 
4.3.5 Mitral Valve 
4.3.6 Cardiac Metastases 
4.3.6 Cardiac Magnetic Resonance Imaging 
4.4 Discussion 
4.5 Conclusion 
 
 
66 
 
4.1 BACKGROUND 
  
Carcinoid tumours occur in between 1 to 2 cases per 100,000 of the 
population. Carcinoid syndrome is thought to occur when the tumour metastases to 
the liver allowing high levels of 5-HT to reach the systemic circulation. Manifestations 
of the syndrome include flushing, diarrhoea, bronchospasm and the development of 
carcinoid heart disease (67).  
5-HT is thought to promote deposition of plaques composed of myofibroblasts 
onto the endocardial surfaces of the heart. Cardiac involvement is commonly 
manifested by the development of right sided valvular dysfunction. Characteristic 
changes include thickening of valve leaflets/cusps which become retracted and 
eventually immobile, resulting in a combination of valvular regurgitation and stenosis 
(5, 6).  
  Significant advances in echocardiography, including the development of  3D 
echocardiography, have allowed greater understanding and assessment of valve 
pathology (68). Secondly, newer imaging modalities such as cardiac magnetic 
resonance imaging have emerged which may allow complimentary assessment of 
cardiac pathology (69).  
 The purpose of this study is to describe the echocardiographic features of 
carcinoid heart disease identifying features of both early and advanced disease and 
to ascertain the value of advanced echocardiographic techniques and other imaging 
modalities. 
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4.2 METHODS 
 
4.2.1 PATIENTS 
 
 Patients with carcinoid syndrome were consecutively and prospectively 
enrolled from April 2006. The diagnosis of carcinoid tumour was based on 
histological examination of either primary tumour or liver metastases biopsy. The 
protocol was approved by the institution‟s ethics committee. All patients gave written, 
informed consent. 
All patients underwent comprehensive 2D TTE. Additional 3D TTE was 
performed after the 2D study from 2008 onwards. 3D TEE was performed where 
transthoracic windows were not suitable for full evaluation of heart valves and there 
was clinical suspicion of valvular heart disease or as part of pre-operative 
assessment prior to valve surgery.   
 
4.2.2. TWO- DIMENSIONAL ECHOCARDIOGRAPHY 
 
2D TTE were performed in all patients using commercially available 
echocardiography machines (Siemens Acuson C512 and Philips iE33). Valve 
morphology and function was evaluated in several views. Valve regurgitation severity 
and quantification were assessed and graded according to The American Society of 
Echocardiography guidelines (52). Valve stenosis was quantified according 
American College of Cardiology Guidelines (53). Pulmonary stenosis was graded 
(according to peak gradient across valve) as mild (<25mmHg), moderate (25 - 
50mmHg) or severe (>50mmHg).Tricuspid stenosis was graded (mean gradient 
68 
 
across valve)  as  mild (2 - 5mmHg), moderate (5 - 8mmHg) or severe (>8mmHg). 
Right and left ventricular function and sizes were assessed and calculated according 
to American Society of Echocardiography guidelines(61).  
All echocardiograms were reviewed by two cardiologists experienced in 
echocardiography. The abnormalities described are based on the consensus of the 
two reviewers. Carcinoid heart disease was defined as the presence of characteristic 
thickening, reduced excursion or retraction of valvular leaflets (with associated 
evidence of valvular stenosis or regurgitation), or the presence of myocardial 
metastases, in the absence of other aetiologies. 
All patients were assessed for the presence of a patent foramen ovale using 
“microbubble” contrast at rest and with cough and Valsalva manoeuvre. The 
presence of patent foramen ovale was defined as the presence of at least 3 
microbubbles in the left atrium within 3 cardiac cycles of contrast visualisation in right 
atrium. The degree of shunting was classified as mild if 3-9 microbubbles appeared, 
moderate if 10 to 30 microbubbles appeared and large if more than 30 microbubbles 
appeared (70).  
 
4.2.3 THREE-DIMENSIONAL TRANSTHORACIC ECHOCARDIOGRAPHY 
 
 3D TTE was performed using Phillips iE33 equipped with X3-1 transducer 
(Philips Medical Systems, Andover, Massachusetts) after 2D examination was 
complete. Full volume, 3D zoom and live datasets were obtained from parasternal, 
apical views and subcostal views. Full volume acquisition was performed over 5 
cardiac cycles with breath hold. Image rendering was performed after the procedure. 
Pyramidal datasets were cropped along x,y,z axes or manually using the cropping 
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plane of choice. Gain settings, smoothing and brightness were adjusted to optimise 
visualisation of valve and valvular apparatus. 
 
4.2.4 THREE DIMENSIONAL TRANSOESPHEAGEAL ECHOCARDIOGRAPHY 
 
 TEE was performed using Phillips iE33 equipped with a X7-2t transducer. 
Multi-plane 2D TEE evaluation was completed followed by acquisition of a 3D 
dataset. A live 3D zoom and full volume dataset was obtained. Images were 
rendered in the same way as for transthoracic echocardiography. 
 
4.2.5 CARDIAC MAGNETIC RESONANCE IMAGING 
 
 Cardiac magnetic resonance imaging was undertaken using commercially 
available 1.5 Tesla MR scanners. Steady state free precession and gradient echo 
pulse sequences were used to assess valve morphology, ventricular function and to 
detect valvular regurgitation. By using phase contrast sequences, the forward and 
regurgitant volumes were calculated from phase-encoded velocity maps.  Delayed 
enhancement gadolinium images were acquired to assess myocardial involvement.  
 
4.2.6 STATISTICAL ANALYSIS 
 
Data are expressed as either median and (first – to – third quartile) or number 
and percentage. The Mann-Whitney U test was used to compare continuous 
variables between groups. The Chi squared test was used to compare groups 
regarding categorical variables; when a cell frequency was less than five, the Fisher 
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exact test was used. All tests of significance were two sided. A probability value (p) 
of <0.05 was considered statistically significant. Statistical analysis was performed 
using StatsDirect Version 2.5.7 (StatsDirect, United Kingdom).  
 
4.3 RESULTS 
 
Two hundred and fifty-two patients were recruited over the study period and 
underwent 2D TTE. Fifty-two patients were found to have abnormalities consistent 
with carcinoid heart disease. 100 patients (40 patients with carcinoid heart disease) 
underwent additional 3D TTE. Twenty-two patients with carcinoid heart disease 
underwent 3D TEE and 10 patients with carcinoid heart disease had a CMR study.   
There were no significant differences in age, sex, tumour characteristics or 
treatments received between those patients with or without carcinoid heart disease. 
Significantly higher levels of urinary 5-hydroxyindolacetic acid and plasma 
Chromogranin A were found in patients with carcinoid heart disease (Table 4.1). 
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Table 4.1 Baseline Demographics 
  Carcinoid Heart Disease P value 
Present (n = 52)                    Absent (n = 200)                 
Age (years)  64 (55 - 69) 64 (58 - 71) 0.4 
Sex (female) 28 (54%) 98 (49%) 0.6 
Duration of diagnosis (months) 5 (1 –  6) 4 (3 - 6) 0.42 
Tumour Grade  Low 48 (92%) 194 (97%) 0.25 
Intermediate 4 (8%) 6 (3%) 0.25 
Presence of Liver Metastases 50 (96%) 171 (86%) 0.06 
Chromogranin A (pMol/L) 1000 (655 - 1000) 140 (56 - 484) <0.0001 
Urinary 5-hydroxyindolacetic  acid 
(ųMol/24 hours) 
800 (399 - 1490) 42 (0 –  205) <0.0001 
Therapies              Somatostatin 
Analogue 
48 (92%) 161 (81%) 0.07 
Interferon 2 (4%) 8 (4%) 0.99 
Chemotherapy 6 (12%) 13 (7%) 0.24 
Surgery 19 (37%) 98 (49%) 0.15 
Targeted 
Radionuclide 
18 (35%) 52 (26%) 0.21 
 
Data are expressed as median and interquartile range or number (%). Picomoles per 
litre (pMol/L), Micromoles (ųMol). 
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4.3.1 RIGHT VENTRICLE, ATRIUM AND TRICUSPID VALVE 
 
  Abnormalities of the tricuspid valve were found in 47 (90%) patients with 
carcinoid heart disease. The mildest changes were thickening of the valve leaflets 
and subvalvular apparatus. The normal concave curvature of the leaflets was 
diminished causing them to become straightened. The dynamic motion of the leaflet 
during diastole was altered. The leaflets moved in a stiff “board like” fashion rather 
than the normal undulating motion. Only trivial or mild centrally directed tricuspid 
regurgitation was noted.  
Thickening of the valve leaflets was associated with thickening of the chordae 
and papillary muscles. Chordae may become fused and shortened. This was 
associated with greater degrees of retraction and reduction excursion of the valve 
cusps. The extent to which each leaflet and subvalvular apparatus was affected was 
variable and produced several patterns of disease (Figure 4.1). 
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Figure 4.1 Two dimensional transthoracic echocardiogram. Right atrium (RA),right 
ventricle (RV), right ventricular outflow tract (RVOT), pulmonary artery (PA).  
A. Diffuse  thickening of septal and anterior tricuspid valve (TV) leaflets (arrow) and 
chordae. Leaflets are  “stiffened” and “board like” and lose their normal curvature. 
Good excursion of the leaflets was present. Trivial/mild tricuspid regurgitation was 
present.  
B. Fixed, thickened septal leaflet of tricuspid valve tethered to ventricular 
endocardium (arrow). Anterior leaflet,  although thickened had good excursion 
(dashed arrow). The tip of anterior leaflet meets body of septal leaflet in diastole 
causing an eccentric jet of moderate tricuspid regurgitation.  
C. Tricuspid valve (TV) leaflets (arrow) are thickened, fixed and retracted. This 
patient had “free flowing” severe tricuspid regurgitation. Both right atrium and right 
ventricle are dilated. 
D. Mild thickening of pulmonary valve cusps. The  cusps are “straightened” and lose 
their normal curvature. 
E.  Grossly thickened, fixed, and retracted  pulmonary valve (PV) cusps (arrow) 
which do not co-apt.  
F. Continuous wave Doppler demonstrating  pulmonary stenosis (PS) with a peak 
gradient of   58 mmHG and peak velocity of  3.8 metres per second and the steep 
deceleration slope of severe pulmonary regurgitation (PR). 
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In the most severe cases leaflets were fixed, retracted and did not co-apt. 
This was associated with severe tricuspid regurgitation with a characteristic “Dagger 
shaped Doppler” profile and mild or moderate tricuspid stenosis (median gradient 
3.5mmHg (interquartile range 2.9mmHg – 4.3mmHG). RV was dilated in 28 (93%) 
patients with severe tricuspid regurgitation (median 3.9cm (interquartile range 3.6cm 
– 4.2cm). The right atrium was enlarged in all patients with severe tricuspid 
regurgitation (median 26cm² (interquartile range 22cm² – 27cm²) (Figure 4.1). 
Three dimensional TTE visualisation of the tricuspid valve allowed an en-face 
view of the valve from either atrial or ventricular side to be obtained. In 22 patients, 
all three leaflets were thickened and fixed in a semi-open position. This caused a 
large area of non-coaptation. Detailed delineation of sub-valvular structures was 
obtained. Gross thickening, shortening and fusion of chordae together with papillary 
muscles was observed (Figure 4.2).  The ability to visualise all three leaflets 
simultaneously allowed comparison between leaflets. Three patients had 
involvement of an isolated septal leaflet. This leaflet was thickened, retracted and 
fixed with preservation of mobility of anterior and posterior leaflets. This caused mal-
coaptation of the cusps. Typically the tip of unaffected leaflet met the body of the 
affected leaflet. This was associated with a moderate, eccentrically directed jet of 
tricuspid regurgitation. 
2D and 3D TEE assessment of the tricuspid valve allowed visualisation of 
valve leaflets in all patients who had poor transthoracic windows. Eighteen (90%) of 
patients with carcinoid heart disease who underwent TEE had thickened right 
ventricular endocardium with probable deposition of carcinoid plaque (Figure 4.2). 
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Figure 4.2 Three dimensional Transthoracic Echocardiogram.  
A. View from the right atrium. Visualisation of anterior, septal and posterior tricuspid 
valve (TV) leaflets (arrow). Thickened tricuspid valve leaflets fixed and retracted 
towards ventricular walls. 
B. Thickening, shortening and fusion of chordae tendinae (dashed arrow) and 
grossly thickened papillary muscles (arrow). 
C. Resected tricuspid valve of patient in panel B. Papillary muscle encased in 
carcinoid “plaque”. Thickening and fusion of chordae tendinae.  Histology confirmed 
plaque composed of myofibroblasts.  
D. View from the right ventricle apex. Thickened tricuspid valve (TV) leaflets (arrow) 
fixed in a semi-open position. Large area of non-coaptation.  
E. Transoesphageal echocardiogram demonstrating carcinoid involvement of 
tricuspid valve (TV) (arrow). Thickened endocardial surface of the right ventricle with 
carcinoid plaque deposition (black dashed arrow). 
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4.3.2 PULMONARY VALVE 
 Abnormalities of the pulmonary valve were found in 36 (69%) of patients with 
carcinoid heart disease. Changes in valve morphology were similar to the tricuspid 
valve. With mild involvement, valve cusps were diffusely thickened which caused 
them to become straightened. With more severe disease varying degrees of 
retraction and reduction in excursion of valve cusps was seen.  In severe cases 
valve cusps were fixed, retracted and thickened with severe pulmonary regurgitation. 
The characteristic sharp deceleration slope of severe pulmonary regurgitation was 
seen. The peak velocity through the pulmonary valve ranged from 1.6 to 3.8 metres 
per second (Figure 4.1). 
3D TTE allowed identification of all three pulmonary valve cusps 
simultaneously. In two patients 3D TTE demonstrated marked thickening of a single 
cusp of the pulmonary valve (demonstrating probable carcinoid plaque deposition) 
with the other two cusps unaffected (Figure 4.3). These abnormalities were not on 
identified on 2D images. Additionally 3D TTE allowed the anatomical relationship 
between all three leaflets and endocardial surfaces as well as the degree of 
coaptation of the cusps to be assessed. In patients with severe disease 3D TTE 
demonstrated constriction of the pulmonary valve annulus with thickened, partially 
retracted and fixed pulmonary cusps causing non-coaptation of the cusps and 
significant stenosis. Post-stenotic dilatation of the pulmonary artery was seen. In 
three patients the arterial surfaces of the pulmonary valve cusps were grossly 
thickened to the extent they completely filled the valve sinus. This made it difficult to 
demarcate the valve cusps from underlying endocardium (Figure 4.3). 
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Figure 4.3 Three dimensional echocardiography of pulmonary valve. Right 
ventricular outflow tract (RVOT), pulmonary artery (PA). 
A. Thickened, fixed and retracted pulmonary valve (PV) cusps (arrow) coupled with 
constriction of pulmonary valve annulus causing severe pulmonary stenosis. 
Pulmonary valve (PV) cusps do not co-apt leading to a large area of non-coaptation 
(dashed arrow). 
B. Post stenotic dilatation of the pulmonary artery (dashed arrow) in a patient with 
carcinoid involvement of the pulmonary valve (PV) and severe pulmonary stenosis. 
Pulmonary valve sinus obliterated and fused with valve cusp (arrow). 
C. Resected pulmonary valve of patient in panel B. Gross, nodular thickening of 
valve cusp causing obliteration of valve sinus (arrow). The normal cusp (*) just being 
discernable on the ventricular surface of the nodule. Inset upper right. 
Histopathological examination. Thickening of valve cusp is due almost entirely to 
deposition of myxoid tissue on the arterial surface of the cusp (arrow) which has 
otherwise retained its normal structure and shape (*) (Alcian Blue – Elastic Van 
Gieson). Inset lower right.  Myxoid tissue is due to proliferation of myofibroblasts, 
shown here as brown-staining spindle cells with an antibody to smooth muscle actin 
(arrow). The cusp itself (*) does not stain with this antibody (Streptavidin-biotin, SMA 
mab @ dilution 1:100, Dako Ltd).  
D. Carcinoid plaque deposition on anterior cusp of pulmonary valve (PV) (arrow)  
with preserved mobility. Other two cusps unaffected.  
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3D TEE provided anatomic information regarding relationship of the all three 
pulmonary valve cusps including the relationship of cusps to the ventricular walls, 
mobility and thickness as well as allowing assessment of pulmonary valve annulus 
constriction and visualisation of right ventricular outflow tract and pulmonary artery.   
 
4.3.4 LEFT SIDED HEART VALVES AND FORAMEN OVALE 
 
Fifteen (29%) patients had left sided valvular involvement.  Thirteen (87%) of 
these were associated with a patent foramen ovale. The two patients with left sided 
disease but without patent foramen ovale both had multiple bronchial carcinoid 
metastases. Three patients with a severe degree of shunting on their bubble contrast 
had severe mitral and/or aortic valve regurgitation. The remaining 10 patients with 
mild or moderate degree of shunting had mild or moderate mitral or aortic 
regurgitation.                
 
4.3.5 AORTIC VALVE 
 
Aortic valve involvement was seen in 14(27%) cases of carcinoid heart 
disease. Diffuse thickening of valve cusps was identified together with mild aortic 
regurgitation. One patient had gross thickening of the non coronary cusp with mild 
thickening of right coronary cusp. Two patients had severe aortic regurgitation. 
Visualisation of the valve cusps was poor on 2D TTE but they were clearly 
thickened. On 2D TEE gross thickening, retraction of all three leaflets which were 
almost fixed leading to non-coaptation of the leaflets was found (Figure 4.4).  
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4.3.6 MITRAL VALVE 
 
Mitral valve involvement was seen in 15 (29%) patients with carcinoid heart 
disease. Similar to the aortic valve, patients had diffuse thickening of both leaflets 
although one patient had a nodular like involvement. Trivial or mild mitral 
regurgitation was present. Three patients had grossly thickened papillary muscles 
and shortened chordae. This caused tenting of the mitral valve leaflets and 
associated severe mitral regurgitation. Although leaflet mobility was restricted no 
significant stenosis was seen. 2D and 3D TEE enabled detailed assessment of the 
sub-valvular apparatus and visualise valve anatomy.  
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Figure 4.4  Left sided Carcinoid Heart Disease. Left ventricle (LV), left atrium (LA), 
aorta (Ao), right atrium (RA), right ventricle (RV). 
 
A. Two dimensional tranoesphageal echocardiogram demonstrating diffusely 
thickened mitral valve (MV) (arrow) and sub-valvular involvement of mitral valve 
chordae (dashed arrow). 
 
B. Two dimensional transoesphageal echocardiogram demonstrating fixed, 
thickened and retracted aortic valve (AV) cusps (arrow). This was associated with 
severe aortic regurgitation. 
 
C.  Two dimensional transthoracic echocardiogram. Diffusely thickened mitral valve 
leaflets, chordae and papillary muscles. Minimal mitral regurgitation was noted. 
 
D.  Resected mitral valve of patient in panel C. Papillary muscle encased in  white 
“carcinoid plaque”. Thickened and partially fused chordae tendinae. Histology 
confirmed plaque composed of myofibroblasts. 
 
 
 
 
 
81 
 
4.3.7 MYOCARDIAL METASTASES 
  
Metastases were detected in 2 (3.8%) of patients with carcinoid heart disease. 
One patient with valvular involvement had a 1.2cm X 10mm metastasis in the right 
atrium and one patient without valvular involvement had multiple metastases in the 
inferior (3.3cm X 2.2cm) and anterior walls (4.1cm X 2.9cm and 3.4cm X 5.6cm) as 
well as basal septum of the left ventricle. Two dimensional TTE and TEE allowed 
visualisation of the cardiac masses. However only an estimate of their diameter 
could be obtained as it was difficult to demarcate the mass from surrounding 
myocardium.  
3D TTE demonstrated better delineation of the mass to adjacent structures. 
CMR allowed identification of location, number, size and relationship of cardiac 
metastases to surrounding structures.  Gallium-68 octreotate positron emission 
tomography demonstrated avid focal uptake in the two masses suggesting 
metastatic spread (figure 4.5).  
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Figure 4.5  
 
A. Tranoesphageal echocardiogram demonstrating large mass in mid to distal 
inferior wall of the left ventricle (arrow). 
 
B.  Three dimensional transthoracic echocardiogram showing well demarcated, 
rounded  mass (arrow) in the posterior wall of left ventricle (LV). 
 
C. Cardiac Magnetic Resonance demonstrating  two well demarcated masses in the 
mid infero-lateral wall extending to the apex (dashed arrow).  Masses are limited to 
myocardium with no extra cardiac extension.  
 
D. Gallium 68 Octreotate PET demonstrating focal avid uptake of  tracer in the 
region of the two masses (arrow) suggesting  metastatic carcinoid tumour. 
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4.3.8 CARDIAC MAGNETIC RESONANCE IMAGING 
  
Ten patients with carcinoid heart disease underwent cardiac magnetic 
resonance imaging (Figure 4.6). Eight patients had dilated right ventricles and 2 
patients had impaired right ventricular function. Thick, fixed and  retracted tricuspid 
valve leaflets which did not co-apt were demonstrated in all 10 patients. 
Quantification of tricuspid regurgitation was severe in all cases. One patient had mild 
tricuspid stenosis.  
Eight out of ten patients had thickened pulmonary valve cusps with restricted 
motion. All of these patients had either mild or moderate pulmonary stenosis. Five of 
these patients had mild pulmonary regurgitation and three had moderate pulmonary 
regurgitation. No patient demonstrated myocardial involvement on late gadolinium 
enhancement imaging.     
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Figure 4.6 Cine Cardiac Magnetic Resonance Imaging. 
A. 4 Chamber View (Systole). Dilated right atrium and ventricle. Thickened, fixed and 
retracted tricuspid valve leaflets (arrow) with associated subvalvular involvement 
(dashed arrow).  
 
B.  Thickening, retraction and reduced excursion of the pulmonary valve leaflets 
(arrow).  
 
C. Phase contrast flow map (short axis view in systole). Severe tricuspid 
regurgitation demonstrated by black retrograde jet (arrow).   
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4.3.9 Pathological Correlation 
  
Twenty-one patients with carcinoid heart disease underwent cardiac valve 
replacement surgery. Gross morphological and histological examination of the 
excised valves was performed in all patients.  The identification of carcinoid heart 
disease in individual valves by echocardiography correlated with findings at 
pathological examination.   
In one patient with severe right sided valvular dysfunction, echocardiography 
demonstrated diffuse thickening of mitral valve leaflets and chordae with trivial 
regurgitation (Figure 4C +D).  At the time of surgery, visual inspection identified 
features of carcinoid heart disease in this valve, therefore mitral valve replacement 
was performed in addition to tricuspid and pulmonary valve replacement. Histological 
examination confirmed the diagnosis. In one patient (with bronchial in addition to 
liver metastases) with severe left sided valvular dysfunction, echocardiography 
demonstrated mild thickening and retraction of pulmonary and tricuspid valves. This 
was associated with mild pulmonary stenosis and moderate tricuspid regurgitation. 
The patient underwent replacement of all 4 valves. Histological examination 
confirmed carcinoid involvement of all valves. 
 
4.6 DISCUSSION 
 
 This study describes the features of carcinoid heart disease encompassing 
the spectrum of disease from early to advanced disease and encompassing both 2D 
and 3D echocardiography as well as cardiac magnetic resonance imaging and  
positron emission tomography  imaging. 
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Echocardiography remains pivotal in the investigation of patients with 
carcinoid syndrome and suspected carcinoid heart disease. The classical features of 
advanced carcinoid heart disease typically involving the tricuspid valve and 
pulmonary valve have been well-described (5, 25, 71).  However the spectrum of 
disease is wide.  
In this study we have identified several patients with diffuse thickening of 
valve leaflets or isolated thickening of a single valve leaflet without significant 
reduction in leaflet mobility or the development of valvular regurgitation. Histological 
examination in two of these patients demonstrated  changes   typical of carcinoid 
heart disease.  Therefore, these findings may represent the early stages of carcinoid 
heart disease.  
We have demonstrated greater involvement of the sub-valvular apparatus and 
valve leaflets can lead to a wide heterogeneous array of appearances and functional 
consequences.  These findings are in keeping with previous necropsy studies (24), 
where the location, extent and pattern of “plaque” deposition on valvular and sub-
valvular  structures is highly variable with both focal and diffuse patterns of plaque 
deposition described.  
Advanced techniques such as 3D TTE or 3D TEE are helpful in identifying 
and assessing valve pathology, particularly in the pulmonary and tricuspid valve, as 
all leaflets may not be visualised on 2D echocardiography. The ability to crop images 
and change the plane of view allowed detailed assessment of the sub-valvular 
apparatus and delineation of the relationship between valve leaflets to each other 
and surrounding structures and the endocardium.  
Cardiac magnetic resonance imaging can be a valuable adjunct in the 
investigation of these patients particularly where echocardiographic windows are 
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poor or structures such as the pulmonary value are difficult to visualise. 
Morphological features of severe carcinoid heart disease can be delineated with 
assessment of valvular regurgitation, stenosis and quantification of ventricular 
volumes. The technique enables measurement of size of metastases and is able to 
offer information regarding extension into extra cardiac structures which is not 
available on echocardiographic techniques. 
Cardiac metastases from carcinoid tumour are rare. In this study 4% of 
patents had cardiac metastases.  Although echocardiographic and cardiac magnetic 
imaging techniques may be able to accurately identify and characterise the mass 
they are not able to elucidate whether it is a carcinoid metastases or another primary 
cardiac tumour. Carcinoid tumours express several somatostatin receptors, 
particularly receptors 2 and 5. Gallium-68 octreotate positron emission tomography 
utilises a somatostatin analogue labelled with gallium-68 tracer. Neuroendocrine 
tumour cells will take up the somatostatin analogue and this will be visible on 
positron emission tomography as it is labelled with Gallium-68. Recent data suggest 
greater than 97% sensitivity and 92% specificity of Gallium-68 octreotate positron 
emission tomography for metastatic deposits in patients with neuroendocrine 
tumours (72).  
 A limitation of the present study is pathological correlation was not available in 
all patients. This was because patients with mild abnormalities or those with 
progressive carcinoid tumour would not undergo valve replacement surgery. The 
number of patients studies may seem relatively small, however, given the relative 
rarity of the condition this represents one of the largest cohorts of carcinoid patients  
studied and a full range of pathology has been described.  
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4.7 CONCLUSIONS 
 
 Carcinoid heart disease is a heterogeneous disease with a wide spectrum of 
echocardiographic findings. An integrated approach using multiple modalities should 
be adopted in patients at risk of developing carcinoid heart disease in order to 
identify  pathology and assess severity of disease. 
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5.1 INTRODUCTION 
 
Gastrointestinal carcinoid tumours are relatively rare, usually slow growing 
malignancies. Carcinoid syndrome occurs when the tumour metastasises to the liver 
and vasoactive amines and peptides secreted by the tumour, including 5-HT, are 
able to reach the systemic circulation. Manifestations of carcinoid syndrome include 
symptoms of flushing, diarrhoea and wheeze (67,73). 
The development of valvular heart disease in these patients, commonly 
termed carcinoid heart disease, is classically characterised by the deposition of 
carcinoid plaque on the endocardium of the right side of the heart. Subsequent 
thickening, retraction and fixation of right sided heart valve leaflets causes a 
combination of valvular regurgitation and stenosis (5). Progression of valvular 
dysfunction eventually leads to right heart failure and significantly impairs survival 
(5,74,).  
The mechanisms for the development of valvular dysfunction are incompletely 
understood.  Elevated levels of 5-HT are thought to be a key mediator in the 
development of carcinoid heart disease (19,20). However, Robiolo et al (19) noted 
more than 50% of patients with elevated 5-HT did not develop carcinoid heart 
disease. Therefore other co-factors may also be involved.   
The identification of potentially modifiable risk factors for the development of 
carcinoid heart disease is desirable. The purpose of the present study was to 
prospectively identify clinical, metabolic, and tumour characteristics which predict 
patients with carcinoid syndrome who are at risk of developing or progression of 
carcinoid heart disease. 
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5.2 METHODS 
 
We conducted an observational cohort study. Patients with histologically 
proven metastatic carcinoid tumour of mid-gut origin and carcinoid syndrome were 
consecutively and prospectively recruited from the neuroendocrine tumour clinic at 
the Royal Free Hospital, London, UK from April 2006. All patients gave written, 
informed consent for the study. The study was approved by the institution‟s local 
ethics committee. 
 
5.2.1 Clinical Evaluation 
 
All patients were evaluated at 4 to 6 monthly intervals in the neuroendocrine 
tumour clinic. Symptoms of carcinoid syndrome were assessed during these visits on 
the basis of a symptom score. This included the number of flushing episodes and 
bowel movement over each 24 hour period for the last 7 days. Patients were 
classified as having symptomatic progression if there was a greater than 50% 
increase in the median daily number of flushing episodes or bowel motions 
compared to either last clinic visit or baseline (i.e the first study) visit. 
 
5.2.2 Biochemical Tumour Markers 
 
5-HIAA and plasma CgA were measured at baseline and at each clinical 
evaluation (4-6 month intervals). 24 hour urine 5-HIAA samples were collected in 
bottles containing acetic acid. Samples were evaluated using reversed phase high 
performance liquid chromatography assay. CgA was measured using DAKO 
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Chromogranin A Enzyme-linked immunosorbent assay (DAKO A/S, Glostrup, 
Denmark). All samples were analysed at the Peptide Laboratory, Hammersmith 
Hospital, London, UK. Patients were classified as having biochemical progression if 
there was a 50% increase of biochemical markers compared to either previous clinic 
visit or the baseline value. 
 
5.2.3 Echocardiography 
 
A baseline comprehensive two dimensional transthoracic echocardiogram 
was performed. Repeat echocardiograms were performed at 6 monthly intervals or 
sooner if clinically indicated. Valve morphology and function was evaluated in 
several views including the use of pulse, continuous wave and colour Doppler. 
Pulmonary valve  was visualised from high parasternal, long axis view of right 
ventricular outflow tract and parasternal short axis view. Tricuspid valve was 
visualised from low parasternal long axis view of right ventricular inflow tract, short 
axis and apical four chamber view. Aortic and mitral valves were assessed from 
parasternal  long axis, short axis, apical four, three and two chamber views. 
 Valvular regurgitation was quantified into grades on the basis of an integrated 
approach including valve morphology, semi-quantitative parameters (colour flow jet 
area/width) and quantitative parameters (vena contracta, proximal isovelocity surface 
area) together with supportive signs in accordance with American Society of 
Echocardiography guidelines (52). Valve stenosis was quantified into grades based 
on parameters recommended by American Society of Echocardiography guidelines 
(53). Tricuspid stenosis was graded (mean gradient across valve) as mild (2 - 
5mmHg), moderate (5 - 8mmHg) or severe (>8mmHg). Right and left ventricular 
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function and sizes were assessed and calculated according to American Society of 
Echocardiography guidelines. Right ventricular diameter was measured at the mid-
cavity of the right ventricle in the apical four chamber view. Right ventricular function 
was measured using fractional area change. Left ventricular ejection fraction was 
calculated by the modified Simpson‟s method from apical four and two chamber view 
(61). 
 
5.2.4 Quantification of carcinoid heart disease 
 
Carcinoid heart disease was defined as the presence of characteristic 
thickening, reduced excursion and retraction of valvular leaflets (with associated 
evidence of valvular stenosis or regurgitation) in the absence of other aetiologies. 
  Quantification of severity was performed by scoring each valve individually.  
The score incorporated leaflet thickness, mobility, retraction and valvular 
regurgitation and stenosis (Table 5.1). Right ventricular size and function were 
graded according to American Society of Echocardiography guidelines. Scores of 0, 
1, 2 and 3 were assigned to normal, mild, moderate and severe right ventricular 
dilatation and dysfunction respectively. The sum of the scores for each valve 
together with the right ventricle score produced a total score. 
All echocardiograms were reviewed and scored by a reader blinded to clinical, 
biochemical and radiological data.  A second reader reviewed and scored a sample 
of  25 (10%) patients to calculate inter-observer variability. A sample of 10 
echocardiograms was re-read to calculate intra-observer variability. Patients were 
defined as having progression of carcinoid heart disease if their score increased by 
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25% or more. Patients were defined as having developed carcinoid heart disease if 
features of carcinoid heart disease was not present on previous echocardiogram. 
 
Table 5.1 Valvular Abnormalities Score 
 
 
5.2.5 Radiological Assessment 
 
A baseline triple phase CT of the thorax, abdomen and pelvis was undertaken. Re-
staging CT scan was performed at 4-6 monthly intervals. All CT scans were reported 
by radiologists with expertise in neuroendocrine tumours.  Radiological assessment 
was based on the RECIST criteria (75). Patients were classified as being 
progression free if a less than 20% increase or 30% decrease in tumour size 
occurred. Patients were classified as having progressive disease if there was a 
greater than 20% increase in size of tumour lesions or the development of new 
lesions. Patients were classified as having an objective (partial) response if tumour 
size decreased by 30% or more. CT scans were compared both to the previous scan 
and the baseline CT scan. 
 Score 
 0 1 2 3 
Leaflet 
Thickness 
< 3mm ≥3mm to 
<4mm 
≥4mm  to 
<5mm 
≥5 mm 
Leaflet Mobility Normal Leaflet 
excursion  
≤75% but 
>50% of 
normal 
Leaflet 
excursion 
≤50% but 
>25% of 
normal 
Leaflet 
excursion  
≤25% of 
normal or 
fixed 
Leaflet 
Retraction 
Normal Mild Moderate Severe 
Valve Stenosis Normal Mild Moderate Severe 
Valve 
Regurgitation 
Normal Mild Moderate Severe 
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5.2.6 Statistical Analysis 
 
Descriptive statistics were used for patients and tumour characteristics at 
study entry. Data are expressed as either median and interquartile range or number 
and percentage. The Mann-Whitney U test was used to compare differences 
between continuous variables and the Chi squared test was used to compare 
categorical variables. When the expected number in any cell was less than five the 
Fisher exact test was used.  For comparison of paired variables the Wilcoxon test 
was used.  Due to the relatively rare incidence of carcinoid tumours, sample size 
was based on identification of all eligible patients within our cohort of patients and 
not on statistical considerations. 
  A time to event analysis was undertaken using a Poisson regression model 
(rather than a survival analysis as there was no natural time zero). Univariate 
Poisson regression analysis was performed to identify risk factors for the progression 
of carcinoid heart disease. The following variables were included in the analysis: 
age, sex (female), progression of biochemical markers (5-HIAA and CgA), 
progression of clinical symptoms (diarrhoea and flushing), progression of liver 
metastases and treatment with chemotherapy, somatostatin analogue, targeted 
therapy and surgical resection. The following continuous variables were 
dichotomized (a priori) for the analysis: CgA (<500pmol/L and ≥500pmol/L), number 
of liver metastases (<5 and ≥ 5), number of flushes over 24 hours (<3 and ≥3) and 
number of episodes of diarrhoea over 24 hours (<5 and ≥ 5). 5-HIAA was split into 4 
groups <300 ųmol/24 hour, ≥300 to 599 ųmol/24 hour, ≥600 to 899 ųmol/24 hour and 
≥900ųmol/24 hour. Multivariate Poisson analysis was performed to identify 
independent predictors of the progression of carcinoid heart disease.  To account for 
96 
 
changes in variables during the study period the following variables were considered 
as time updated variables: 5-HIAA, CgA, episodes of diarrhoea and flushing. 
Therefore the effect of the most recent level of the variable on the outcome was 
considered. Inter-observer agreement between echocardiography readers was 
expressed as the percentage with exact agreement. All tests of significance were 
two sided. A probability value (p) of <0.05 was considered statistically significant. 
Statistical analysis was performed using StatsDirect Version 2.5.7 (StatsDirect, 
United Kingdom).  
 
5.3 RESULTS 
 
 Two hundred and fifty-two patients were recruited. Median follow up was  29 
months (interquartile range, 24-36).  At baseline 41 patients had carcinoid heart 
disease. 44 patients either developed carcinoid heart disease during the study period 
or had progression of existing carcinoid heart disease (15 patients developed and 29 
patients progressed). 34 patients died during the study period (13 patients had 
carcinoid heart disease). 5 patients were lost to follow up during the study period. 
 Baseline demographics are reported in table 5.2.  There were no significant  
differences between those with progression of carcinoid heart disease and those 
without progression in terms of baseline age, sex, follow-up, duration of diagnosis of 
carcinoid tumour, presence of liver metastases or treatment modalities received. 
There were significantly greater baseline levels of 5-HIAA and Chromogranin in 
those patients with progression of carcinoid heart disease. 
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Table 5.2 Baseline Demographics 
 
 
 
Data are expressed as median and interquartile range or number (%). Picomoles per 
litre (pMol/L), Micromoles (ųMol). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Progression of 
Carcinoid Heart 
Disease 
(n = 44) 
No Progression 
of Carcinoid 
Heart Disease 
(n = 208) 
P value 
Age (years) 60 (55-67) 63 (55-69) 0.35 
Sex (Female) 22 (50%) 110 (52.9%) 0.86 
No of Echocardiograms 5 (3.5 – 6) 5 (3 – 6) 0.09 
Follow up (Months) 32 (24-36) 29 (24-34) 0.10 
Duration of diagnosis of 
carcinoid tumour(Months) 
5 (3-6) 4 ( 3- 7) 0.67 
Tumour 
Grade 
Intermediate 4 (9.1%) 11 (5.3%) 0.31 
Low 40 (90.9%) 197 (94.7%) 0.31 
Presence of Liver 
Metastases 
42 (95.5%) 186 (89.4%) 0.27 
Therapy Somatostatin 
Analgoue 
42 (95.5%) 178 (85.6%) 0.08 
Duration of 
somatostatin 
therapy 
(months) 
29.5 ( 18- 44) 27 (18 – 41) 0.85 
Interferon 4 (9.1%) 10 (4.8%) 0.28 
Chemotherapy 4 (9.1%) 12 (5.8%) 0.49 
Targeted 
Radionuclide 
17 (38.6%) 56 (27%) 0.14 
Surgical 
Resection 
15 (34.1%) 100 (48.3%) 0.10 
5-Hydroxyindolacetic Acid 
(ųMol/24 hours) 
465 (244 -1324) 46.5 ( 0-205) <0.001 
Chromogranin A (pMol/L) 990 ( 323-1000) 206 (72 – 529) <0.001 
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5.3.1 Changes in Clinical, Biochemical and Radiological Parameters 
 
In patients with development or progression of carcinoid heart disease there 
was a significant increase in levels of 5-HIAA (median 791ųmol/24hr (interquartile 
range, 581 to1084)) and episodes of flushing (median 4.5 episodes per 24hours 
(interquartile range, 4 to 6)) at the time of progression  compared to the previous 6 
months (median 5HIAA 460.5 ųmol/24hr (interquartile range, 309 to 948.5) and  
median flushing episodes per 24 hours, 2 (interquartile range 1 to 3)).  There were 
no significant changes in median levels of CgA or episodes of diarrhoea during the 
same period (Table 5.3).  Nineteen of the 44  patients (43%) with progression of 
carcinoid heart disease had an increase in the size of liver metastases (progressive 
disease by RECIST criteria on CT). 
In patients without development or progression of carcinoid heart disease 
there was no significant change in median levels (baseline compared to peak) of 5-
HIAA, CgA or episodes of either diarrhoea or flushing during the study period (Table 
3). Twenty-five out of 208 patients (12%) without progression of carcinoid heart 
disease had an increase in the size of liver metastases (progressive disease by 
RECIST criteria on CT) 
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Table 5.3 Changes in clinical, biochemical parameters during the study period 
 
 Progressive Carcinoid Heart Disease (n=44) 
At Time of 
Progression 
Previous 6 Months Significance 
5-Hydroxyindolacetic Acid 
(ųMol/24 hours) 
791 (581-1084.5) 460.5(309-948.5) 0.001 
Chromogranin A 
(pMol/L) 
1000(428.5-1000) 976.5(323-1000) 0.17 
Episodes of flushing per 
24 hours 
4.5 (4-6) 2.0 (1-3) <0.001 
Episodes of diarrhoea per 
24 hours 
2 (2-3) 3 (2-4.5) 0.09 
 No progression of Carcinoid Heart Disease (n=208) 
Baseline Peak Significance 
5-Hydroxyindolacetic Acid 
(ųMol/24 hours) 
52.5(0-205) 55(0-205) 0.09 
Chromogranin A 
(pMol/L) 
206(72-520) 209.5(68.5-561.5) 0.08 
Episodes of flushing per 
24 hours 
1(0-1) 1(0-1) 0.45 
Episodes of diarrhoea per 
24 hours 
2(1-3) 2(0.5-3) 0.45 
Data are expressed as median and interquartile range. Picomoles per litre (pMol/L), 
Micromoles (ųMol). 
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5.3.2 Risk factors for the progression and development of carcinoid heart 
disease 
 Incidence Rate ratio (IRR) for the development or progression of carcinoid 
heart disease are displayed in table 5.4. Flushing of greater than 3 episodes over 24 
hours, progressive symptoms (flushing), 5-HIAA levels of ≥300 to 599 ųmol/24hr, 
5HIAA ≥600 to 899 ųmol/24hr, 5HIAA ≥900ųmol/24hr, progression of 5-HIAA, the 
presence of more than 5 liver metastases and progression of liver metastases were 
associated with progression of carcinoid heart disease. 
 In a multi-variate model (table 5.5) independent predictors of the 
development or progression of carcinoid heart disease were flushing of greater than 
3 episodes per 24 hours and 5-HIAA levels of ≥300.  There was stepwise increase in 
the risk of progression of carcinoid heart disease as levels of 5-HIAA increased. 
Compared to those patients with a 5HIAA <300 ųmol/24 hour, those who had  5HIAA 
levels of ≥300 to 599, 600-899 and >900 ųmol/24 hour had 2.74, 3.16 and 3.40 times 
the risk of progression of carcinoid heart disease, respectively. 
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Table 5.4 Univariate Analysis of Risk Factors For The Development and Progression 
of Carcinoid Heart Disease 
 
Picomoles per litre (pMol/L), Micromoles (ųMol). 
 
 
 
 
 
 
Parameter Incidence rate 
ratio 
95% 
Confidence 
Interval 
Significance 
Age 0.99 0.97-1.02 0.49 
Sex (Female) 0.87 0.48-1.57 0.64 
Diarrhoea >5 stools/24 hours 1.95 0.94- 4.05 0.08 
Progressive Symptoms (Diarrhoea) 1.27 0.53 – 3.01 0.58 
Flushing > 3 episodes/24 hours 26.87 10.59 – 
68.18 
<0.001 
Progressive Symptoms  (Flushing) 21.46 9.98 – 46.20 <0.001 
5-
Hydroxyindolacetic 
Acid (ųMol/24hours) 
<300  0.01 0.00 – 0.09 <0.001 
300 – 599 3.26 1.76 – 6.02 <0.001 
600 – 899 4.51 2.36 – 8.61 <0.001 
>900 5.17 2.71 – 9.89 <0.001 
Progressive Biochemical Markers 
(5-HIAA) 
10.07 5.56 – 18.23 <0.001 
Chromogranin A > 500 pMol/L 1.73 0.95 – 3.15 0.07 
Progressive Biochemical Markers 
(CgA) 
1.82 0.84 – 3.91 0.13 
>5 Liver Metastases 4.19 1.95 – 9.01 <0.001 
Progressive Disease (Radiological) 2.85 1.57 – 5.17 <0.001 
Tumour Grade - Intermediate 0.55 0.20 – 1.55 0.26 
Therapy Chemotherapy 1.39 0.50 – 3.89 0.53 
Somatostatin 
Analogue 
1.75 0.54 – 5.63 0.35 
Targeted 
Therapy 
1.63 0.90 – 2.96 0.11 
Interferon 0.98 0.30 – 3.16 0.97 
Surgical 
Resection 
0.54 0.29 – 1.03 0.06 
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Table 5.5  Multi-variate Analysis of Risk Factors For The Development and 
Progression of Carcinoid Heart Disease 
 
Factor Incidence 
Rate Ratio 
95% 
Confidence 
Interval 
Significance 
Flushing > 3 episodes per 24 hours 5.20 1.33 – 20.40 0.02 
Progressive Symptoms (Flushing) 2.72 0.87 – 8.50  0.08 
5-Hydroxyindolacetic 
Acid (ųMol/24hours) 
300 – 599 2.74 1.13 – 6.65 0.03 
600 – 899 3.16 1.07 – 9.36 0.04 
>900 3.40 1.42 – 8.17 0.01 
Progressive Biochemical Markers (5-
Hydroxyindolacetic acid 
1.45 0.69 – 3.03 0.33 
> 5 Liver Metastases 0.88 0.38 – 2.04 0.77 
Progressive Tumour (Radiological) 1.23 0.64 – 2.37 0.53 
 
Picomoles per litre (pMol/L), Micromoles (ųMol). 
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5.3.3 Rate of development and progression of valvular abnormalities 
 
 The overall rate of the development or progression of carcinoid heart disease 
was 7.4 events per 100 person-years. Fifteen patients developed carcinoid heart 
disease during the study (median score 15 (interquartile range, 8 to 20)). Nine of 
these had involvement of both tricuspid and pulmonary valves. One patient had 
isolated pulmonary valve involvement and 5 patients had isolated tricuspid valve 
involvement. Seven of the 14 patients with tricuspid valve involvement had severe 
tricuspid regurgitation and 4 of the 10 patients with pulmonary valve involvement had 
either severe pulmonary regurgitation or stenosis. 
 Twenty-nine patients had progression of existing carcinoid heart disease 
(baseline median score 9 (interquartile range, 7 to 12) and post progression median 
score 22 (interquartile range, 13 to 26)). All patients had worsening of valvular 
stenosis or regurgitation by more than 1 grade. Nineteen of the twenty nine had 
worsening of valvular stenosis or regurgitation by two grades. 5 patients had 
worsening of valvular stenosis or regurgitation by more than 3 grades. Six of the 29 
patients developed new left sided valvular lesions. In 4 of these patients a patent 
foramen ovale was present and bronchial metastases were present in 2 patients. An 
example of a patient whose carcinoid heart disease progressed is given in figure 5.1. 
No patient showed regression of carcinoid heart disease. 
Of the 25 studies scored by both readers, exact inter-observer  agreement  
was present in 20 (80%) patients. Three patients scores differed by 1 points and 2 
patients score differed by two points. Exact intra-observer variability was present in 9 
out of the 10 studies reviewed. 
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Figure 5.1  Baseline and follow-up echocardiogram demonstrating progression of 
carcinoid heart disease 
. 
A. Baseline echocardiogram. Right atrium (RA), Right Ventricle (RV). Thickened 
tricuspid valve (TV) leaflets. The leaflets have normal excursion although there is 
mal-coaptation at the leaflet tips. 
B. There is  mild tricuspid regurgitation (TR). 
C. After 9 months the patient symptoms of carcinoid syndrome deteriorate. She 
experiences 5 to 6 flushing episodes per day. Her 5-HIAA is elevated at 
790ųMol/24hours. The right ventricle and atrium are now dilated. The tricuspid valve 
leaflets are now fixed, retracted and do not co-apt. 
D. There is now severe tricuspid regurgitation.  
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5.4 Discussion 
 
 The development of carcinoid heart disease and subsequent development of 
right sided heart failure is a major cause of morbidity in patients with carcinoid 
syndrome. The risk factors for development and progression of carcinoid heart 
disease are poorly defined.  
In this study independent predictors of the development and progression of 
carcinoid heart disease were a 5-HIAA greater than 300 ųmol/24hr or symptomatic 
flushing of greater than 3 episodes per day. Based on unadjusted univariate 
analysis, progression of liver metastases and those patients with more than five 
metastases were predictors of the development of carcinoid heart disease.  However 
they were no longer significant in the multi-variate model. This suggest only where 
the progression of liver metastases lead to high levels of  hormone production are 
they significant for development of carcinoid heart disease.  
Moller et al (20) found elevated levels of 5-HIAA and the use of chemotherapy 
to be associated with progression of carcinoid heart disease. However the study was 
limited due to a retrospective design and possible selection bias as over 50% of the 
sample population were excluded as serial echocardiograms were not available. 
Denney et al (76) performed a prospective study however only 23 patients with 
carcinoid syndrome were studied. This study is a large, prospective, longitudinal 
study with serial measurements of echocardiographic, clinical, biochemical and 
radiological parameters. 
 Current treatment objectives in these patients are the improvement of 
symptoms of carcinoid syndrome and also the control of tumour growth (73). The 
mainstay of therapy is the administration of long acting somatostatin analogues 
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which have been shown to produce a biochemical response in up to 60% of patients 
and symptomatic response in between 40 - 80 % of patients (77). However at 
present there are no recommended targets for reduction in biochemical markers or 
clinical symptoms. A 5-HIAA level above 300 ųmol/24hr confers a two to three fold 
increase in risk in developing carcinoid heart disease and having greater than 3 
flushing episodes a day confers a five-fold risk. Therefore a therapeutic strategy to 
reduce development of carcinoid heart disease may be to aim to reduce 5-HIAA and 
flushing episodes below these levels.   
 The majority of patients who developed carcinoid heart disease were already 
receiving somatostatin analogues. Although a strategy of dose escalation of 
somatostatin analogue may be used initially, eventually patients may become 
refractory to somatostatin analogues (78). Both hepatic artery embolisation with or 
without intra-arterial chemotherapy (79,80,81)  and alpha-interferon (82) have been  
shown to be effective in reducing symptoms and biochemical markers in 
appropriately selected patients with carcinoid  syndrome who become refractory to 
somatostatin analogues. Evidence for the use targeted radionuclide therapies in this 
context is slowly emerging (83). 
 5-HT is thought to be a major mediator in the development of valvular 
dysfunction in patients with carcinoid syndrome. 5-HT has been shown to up-
regulate TGF-β  and  stimulate collagen synthesis in human aortic interstitial cells 
(15,16). In animal models long term administration of 5-HT has been shown to 
induce development of subendocardial plaque composed of  myofibroblasts within a 
collagen matrix on heart valves (17). These histopathological changes are similar to 
those found in carcinoid heart disease. 
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   Robiolio et al (19) noted 5-HIAA has a very high sensitivity but low specificity 
as a marker of valvular dysfunction in patients with carcinoid syndrome. This 
suggests other co-factors may be necessary for the development of pathology. Our 
study suggests high levels of daily flushing is also a marker of development and 
progression. The aetiology of the carcinoid flush is not fully characterised. However it 
is thought a range of  vasoactive substances including 5-HT, tachykinins as well as  
prostaglandins  are responsible (84). Indeed Lundin et al (6) noted elevated levels of 
the tachykinins (substance P and neurokinin A) in patients with valvular dysfunction 
and carcinoid syndrome.  Both these markers are also known to stimulate fibroblast 
proliferation (85). Therefore it is likely the combination of hormones is required for 
development of valvular heart disease in patients with carcinoid syndrome. 
 The lower prevalence of valvular dysfunction and rate of development of 
valvular dysfunction in this study contrasts with echocardiographic screening studies 
from over two decades ago where nearly 60% of patients with carcinoid syndrome 
had evidence of valvular dysfunction (5,56).  This may be partly explained by the use 
of somatostatin analogue being substantially greater in our cohort (90.5%) compared 
series from the 1980s where either limited (57%) or no somatostatin analogue was 
used (5,56). In 65% of patients with progression of valvular dysfunction the grade of 
valvular stenosis or regurgitation increased by more than 2 grades in less than 6 
months. In 17% of patients this increased by more than 3 grades in this time frame. 
Although classically carcinoid tumours have been thought of slow growing the effects 
of high hormone load on the cardiac structure and the development of valvular 
dysfunction may be rapid.   
 A possible limitation of the study is there are no standardised criteria for 
quantifying the progression of carcinoid heart disease. Similar to previous studies 
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(20) we used an echocardiographic score and chose a cut-off valve of 25% increase 
in the score for our definition of the progression of carcinoid heart disease. Using this 
score there was a good inter and intra observer agreement.  
This study has identified predictors of the development and progression of 
valvular heart disease in these patients.  Clinical trials would be needed to test the 
hypothesis that modulation of these risk factors may attenuate the development of 
valvular heart disease in patients with carcinoid syndrome.  
 
5.5 CONCLUSION 
 
  In conclusion elevated 5-HIAA > 300 ųmol/24hr and daily flushing 
episodes greater than 3 are predictors of the development and progression of 
carcinoid heart disease.  The development of valvular dysfunction may be rapid with 
severe dysfunction occurring within a short time period.  
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6.1BACKGROUND 
 
Gastrointestinal carcinoid tumours are relatively rare slow growing 
malignancies. A proportion will develop carcinoid syndrome which is the result of the 
release of a range of vasoactive peptides and hormones that reach the systemic 
circulation, without being metabolised by the liver. Symptoms of “carcinoid 
syndrome” include flushing, diarrhoea, bronchoconstriction as well as the 
development of carcinoid heart disease (2). 
 Carcinoid heart disease develops in between 20 and 60% of cases of 
carcinoid syndrome (5). Deposition of fibrotic plaque on endocardial surfaces is 
thought to be mediated by  high levels of  5-HT (86).  Characteristically valvular 
dysfunction involves the tricuspid and pulmonary valve although left sided valvular 
dysfunction may also occur (87). 
The prognosis of patients with carcinoid heart disease treated medically is 
poor (5). Cardiac valve replacement surgery for patients with carcinoid heart disease 
has been advocated in patients with symptomatic carcinoid heart disease. An 
improvement in functional class post operatively has been observed (38). Surgical 
mortality is high with case series reporting 30 day mortality rate of between 10% up 
to 60% (38,39,40). Reported peri-operative complications include right ventricular 
failure, renal dysfunction, sepsis and carcinoid crises. 
Due to the relative rarity of the disease experience in the field of valve surgery 
for carcinoid is limited. Most data is limited to patients operated on over a decade 
ago in US series (38,40). We sought to investigate outcomes, complications and 
predictors of survival of cardiac surgery in a contemporary cohort of patients in 
Europe. 
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6.2 METHODS 
 
6.2.1 PATIENT GROUP 
 
All patients referred to the neuroendocrine tumour unit  with carcinoid tumour 
of mid-gut origin and carcinoid syndrome were screened for the presence of 
carcinoid heart disease. Serial follow-up echocardiograms were performed in all 
patients. Patients with carcinoid heart disease were followed in a specialist valvular 
heart disease clinic at 6 monthly intervals. Patients were referred for valve surgery if 
they met the following criteria: (1) stable carcinoid tumour (2) severe valvular 
dysfunction (3) symptomatic and (4) had no other significant co-morbidities. The 
study was approved by the institutional ethics committee and all patients gave 
written informed consent. 
 
6.2.2 Echocardiography 
 
All patients underwent comprehensive two dimensional echocardiograms to 
assess each valve for the presence of carcinoid involvement and the severity of 
valvular dysfunction. Valve morphology and function was evaluated in several views. 
Pulmonary valve was visualised from high parasternal, long axis view of right 
ventricular outflow tract and parasternal short axis view. Tricuspid valve was 
visualised from low parasternal long axis view of right ventricular inflow tract, short 
axis and apical four chamber view. Aortic and mitral valves were assessed from 
parasternal  long axis, short axis, apical four, three and two chamber views. Valvular 
regurgitation and stenosis were assessed and graded  according to The American 
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Society of Echocardiography guidelines (52,53). Pulmonary stenosis was graded 
(according to peak gradient across valve) as mild (<25mmHG), moderate (25-
50mmHg) or severe(>50mmHG).Tricuspid stenosis was graded (mean gradient 
across valve)  as  mild (2 - 5mmHg), moderate ( 5- 8mmHg) or severe(>8mmHg). 
A contrast echocardiogram was performed to detect the presence of a patent 
foramen ovale using “microbubble” contrast at rest and with cough and Valsalva 
manoeuvre. The presence of patent foramen ovale was defined as the presence of 
at least 3 “microbubbles” in the left atrium within 3 cardiac cycles of contrast 
visualisation in right atrium. 
 
6.2.3 Biochemical Testing 
 
Urinary 5-HIAA, plasma  CgA  and NT-proBNP were measured. 24 hour urine 
5-HIAA samples were collected  in bottles containing acetic acid. Samples were 
evaluated using reversed phase high performance liquid chromatography assay. Cg 
A samples were taken from antecubital fossa in a serum gel tube. CgA was 
measured using DAKO Chromogranin A Enzyme-linked immunosorbent assay 
(DAKO A/S, Glostrup, Denmark). NT-proBNP samples were taken from the left 
antecubital fossa at room temperature in a serum gel tubes. Analysis was 
undertaken immediately, after being centrifuged, by Roche Modular Analytics E-170 
immunoassay analyser using an electrochemilunescence detection. 
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6.2.4 Cardiac Catheterisation 
 
All patients underwent cardiac catheterisation and coronary angiography to assess 
the presence or absence of coronary artery disease. 
 
6.2.5 Anaesthetic Management 
 
All patients were started on an Octreotide infusion of 50mcg/hour 12 hours prior to 
surgery and for 48 hours post-surgery. After this period they were started on 
subcutaneous Octreotide 200mcg three times a day for the next 14 days. Thereafter 
they were recommenced on their long acting somatostatin analogue. 
 
6.2.6 Cardiac Surgery 
 
 Surgery was performed on aorto-bicaval cardiopulmonary bypass through a 
midline sternotomy. Systemic temperature was lowered to 32°C. Myocardial 
protection was achieved through antegrade as well as retrograde cold blood 
cardioplegia. Details of  individual operations are  summarised in table 1. Tricuspid, 
mitral and aortic valves were replaced with pericardial tissue valves. The pulmonary 
valves was replaced with a cryopreserved pulmonary homograft. If a patent foramen 
ovale was present this was closed with a simple prolene suture. If the patient had 
documented atrial fibrillation a Cox Maze procedure was carried out. Intra-operative 
transoesphageal echocardiograms were performed routinely. 
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6.2.7 Statistical Analysis 
 
 Patient characteristics are reported as median and inter-quartile range 
or number and percentage. Kaplan Meier survival analysis curves were formulated to 
demonstrate overall survival. Survival curves were formulated to compare the 
following groups of patients: NYHA I/II vs NYHA III/IV, NT-proBNP above median 
level for the cohort (> 1245pg/ml vs NT-proBNP <1245 pg/ml) and mild/moderate 
right ventricular dysfunction versus severe dysfunction. Differences in survival 
between stratified groups was analysed by Peto‟s log rank test. All tests of 
significance were two sided. A probability value (p) of <0.05 was considered 
statistically significant. Statistical analysis was performed using StatsDirect Version 
2.5.7 (StatsDirect, United Kingdom).  
 
6.3 RESULTS 
 
Two hundred and fifty-two patients were screened during the study period. 52 
patients had carcinoid heart disease. 40 patients developed severe valvular 
dysfunction during the study period. Of these 22 (55%) patients underwent cardiac 
valve surgery during the study period. Reasons for not being referred for valve 
replacement surgery included: severe right ventricular dysfunction in   3 patients, 
poorly controlled symptoms of carcinoid syndrome in  3  patients, progressive 
increase in tumour size in 8  patients,  patient choice in  3 patients and being 
asymptomatic in 1 patient. 
 Demographics of the group are in table 6.1.The median age of patients was 
60. The majority of patients were in NYHA Class II (50%) and III (36.4%) prior to 
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surgery.  The medical management consisted of loop diuretics (90.9%) and 
aldosterone antagonists (50.1%).  NT-proBNP. 5-HIAA and CgA were elevated in all 
patients. 
The operative procedures performed are summarised in table 6.2. Three 
patients underwent tricuspid valve replacement alone, 15 patients underwent 
tricuspid and pulmonary valve replacement, 1 patients underwent tricuspid, 
pulmonary and mitral valve replacement and 2 patients underwent replacement of all 
4 cardiac valve. Patent foramen ovale was closed in all patients with left sided 
carcinoid heart disease.  One Patient underwent concurrent coronary artery bypass 
grafting in addition to tricuspid and pulmonary valve replacement. Cox Maze 
procedure was performed in 2 patients. 
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Table 6.1 Baseline Demographics 
Characteristic Number (%) 
Age 60 (50-65) 
Sex (Female) 11 ( 50%) 
Duration of Diagnosis 4 (3-6) 
Presence of Liver Metastases 22 (100%) 
Chromogranin A (pmol/L) 1000 (688-1000) 
5-Hydroxyindolacetic Acid ( μmols/24hours) 787.5(340-979) 
N-Terminal Brain Natriuretic Peptide (pg/ml) 1245 (381-2083) 
Glomerular Filtration Rate (mls/min) 70 (60 – 79) 
Hypertension 4 (18.2%) 
Diabetes 3 (13.6) 
Previous Cardiac Valve Surgery 1 (4.5%) 
New York Heart 
Association 
Class 
I 1 (4.5% 
II 11 (50%) 
III 8 (36.4%) 
IV 2 (9.1%) 
Medication Loop Diuretics 20 (90.9%) 
Aldosterone Antagonists 13 (59.1%) 
Angiotensin Converting 
Enzyme Inhibitors 
2 (9.1%) 
Signs of right 
heart failure 
Ascites 2 (9.1%) 
Leg Oedema 15 (68%) 
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Table 6.2 Operative Procedures Performed 
 
Procedure Number (%) 
Tricuspid Valve Replacement 22 (100%) 
Pulmonary Valve Replacement 15 (68.2%) 
Mitral Valve Replacement 3 (13.6%) 
Aortic Valve Replacement 2 (9.1%) 
Closure of Patent Foramen Ovale 9 (40.9%) 
Cox Maze Procedure 2 (9.1%) 
Coronary Artery By-Pass Grafting 1 (4.5%) 
Excision of Cardiac Metastases 1 (4.5%) 
 
 
Overall 30 day peri-operative mortality was 18.2% (4 patients).  Causes of 
death were right ventricular dysfunction in 2 patients and stroke with aspiration 
pneumonia in 1 patient and carcinoid crisis in 1 patient. Median length of hospital 
stay was 10 days. Complications occurring within the immediate 7 day post-
operative period were: persistent complete heart block requiring permanent 
pacemaker implantation in 4 patients, sustained ventricular tachycardia requiring 
cardioversion in one patient, carcinoid crisis in 1 patient and acute renal failure 
requiring hemofiltration in 2 patients. 4 patients developed marked hypoalbuminemia 
in the post-operative period. 
    In those that survived the initial operation median follow up was 26 months 
(8 – 42). Overall 12 (67%) patients experienced significant symptomatic 
improvement post-surgery (greater than 1 grade improvement in NHYA Class) (table 
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6.3).  I and 2 year survival rates were 55.6% and 44.4% respectively.  There was no 
significant difference in survival between those in NYHA Class I and II and those in 
NYHA classes III and IV (figure 6.1), p= 0.49. There was no significant difference in 
survival between those with a NT-proBNP greater than 1245pg/ml compared to 
those with a NT-proBNP below 1245 pg/ml (figure 6.2), p=0.43. No significant 
differences in survival was found between those with mild/moderate pre-operative 
right ventricular dilatation and those with severe dilatation (figure 6.3), p= 0.91. 
 
Table 6.3 Functional New York Heart Association Class Pre and Post Cardiac Valve 
Surgery. 
 Prior to surgery 3 months post surgery 
New York 
Heart 
Association 
Class 
I 1  11 
II 9 5 
III 7 2 
IV 1  0 
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Figure 6.1 Kaplan-Meier Survival Curves Stratified according to New York Heart 
Association Class 
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Figure 6.2 Kaplan-Meier Survival Curves  Stratified according to N Terminal-pro 
Brain Natriuretic Peptide 
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Figure 6.3 Kaplan-Meier Survival Curves  Stratified according to Right Ventricular 
Size 
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 In the patients who died more than 30 days post surgery causes of death 
were: progression of carcinoid tumour in 4 patients (22%), right ventricular failure in 
1 patient (5.5%), pneumonia in 2 patients (11%) and cause unknown in 1 patient 
(5.5%). During follow-up 2 patients developed degeneration of their bio-prosthetic 
valve. One patients developed moderate pulmonary stenosis of a pulmonary 
homograft and one developed moderate tricuspid regurgitation due to degeneration 
of a bio-prosthetic tricuspid valve. No patient required re-operation for bio-prosthetic 
degeneration 
 
6.4 DISCUSSION 
 
 The development of carcinoid heart disease imparts reduced survival and 
significant morbidity (41). Symptoms of right heart failure can considerably impair 
quality of life. Data on outcomes and risk of cardiac surgery in these patients has 
been limited to case reports and small case series in US patients (38,39,40). There 
are no studies on European patients. Standard surgical risk assessment such as 
Euroscore or STS Scoring system are based on data for patients undergoing 
coronary artery bypass grafting and aortic and mitral valvular disease (88,89). 
 In this cohort, 55% of patients with severe valvular dysfunction were referred 
for cardiac valve replacement surgery. The large proportion of patients who were not 
suitable for valve surgery reflects the complex nature of these patients. Complication 
including bowel obstruction, mesenteric ischaemia, uncontrolled symptoms of 
carcinoid syndrome or progressive increase in size of tumour require resolution prior 
to considering cardiac valve replacement.  
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Our data confirm previous finding of a high peri-operative risk. In our series 30 
day mortality was 18.2%. This is line with data from New York of 20% and the Mayo 
clinic of between 10 and 30% (38,39).  Complications included right ventricular 
dysfunction, carcinoid crisis, renal failure and sepsis. A large proportion of patients 
required a pacemaker implantation for complete heart block.  A larger proportion 
developed asymptomatic conduction disorders.  
Our data showed the majority of patients who survived valve surgery showed 
symptomatic improvement. Increased NYHA class, elevated BNP level and severe 
RV dilatation impart an impaired prognosis in those patients with carcinoid heart 
disease treated medically (7,41). However in our cohort, in those that survived the 
initial operation, pre-operative NYHA class, NT-proBNP level or RV size did not 
predict long term post-operative survival. This may be explained by a large number 
of  late deaths due to complications  related to the metastatic carcinoid tumour 
occurring during the follow-up period. This is in keeping with previous data where 
NYHA class and  right ventricular enlargement did not affect not long term survival 
after valve surgery for carcinoid heart disease (38). 
 The indication and optimal timing of valve replacement surgery in carcinoid 
heart disease is controversial. Our data suggest valve replacement is indicated in 
symptomatic patients. There is no data to support the use of valve replacement 
surgery in asymptomatic patients with or without dilatation of the right ventricle. 
In our cohort, 4 patients noticed a marked reduction in serum albumin for 
several weeks post valve surgery which resulted in generalised oedema. This may 
well be due to physiological stress and associated inflammatory response evoked by 
surgery. However it poses particular problems for the patients with carcinoid tumour. 
Patients with carcinoid tumour may have underlying nutritional deficiencies. Patients 
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with advanced carcinoid may have mesenteric fibrosis with desmoplasia. This may 
cause partial compression of branches of the superior mesenteric artery and vein 
leading to subsequent development of mesenteric ischemia and post-prandial pain. 
This may manifest as weight loss, malnutrition and cachexia (90). Our patients found 
it difficult to increase their calorie intake and required intensive nutritional support in 
the post-operative period.  As a result we now have a specialist dietician in 
neuroendocrine tumours to assess patients both pre and post-operative period. 
 The choice of valve replacement has been debated in the literature. There 
have been isolated reports of bio-prosthetic degeneration (43,44). In our series only 
two patients showed evidence of valve degeneration. Neither of these was severe 
enough to either cause symptoms or require further intervention. Mechanical 
replacement of the tricuspid valve is associated with a higher risk of thrombosis 
compared to bio-prosthetic valves (46,91). Compounding problems in patients with 
carcinoid tumours include the risk of haemorrhage in patients with liver metastases 
and management of perioperative anti-coagulation if patients need non-cardiac 
surgery such as resection of liver metastases. 
 
CONCLUSION 
  
Valve surgery for carcinoid heart disease is higher risk than most other forms 
of valvular surgery. However in those that survive the operation significant 
improvement in functional class occurs. Bio-prosthetic valve degeneration was not 
significant in our series. Most long term complications were related to the tumour 
itself rather than cardiac complications. 
 
125 
 
CHAPTER 7: DISCUSSION 
 
7.1 INTRODUCTION 
7.1 CLINICAL FEATURES  
7.2 THE VALUE OF CARDIAC BIOMARKERS IN CARCINOID HEART DISEASE 
7.3 ROLE OF CARDIAC IMAGING IN CARCINOID HEART DISEASE 
7.4. RISK FACTORS FOR THE DEVELOPMENT AND PROGRESSION OF 
CARCINOID HEART DISEASE 
7.5 CLINICAL OUTCOMES AND COMPLICATIONS OF CARDIOVASCULAR  
SURGERY 
7.6 CONCLUSION 
 
 
 
 
 
 
 
 
 
 
 
 
 
126 
 
7.1 INTRODUCTION 
 
Carcinoid heart disease is a rare, but unique form of valvular heart disease 
occurring in patients with carcinoid syndrome. Although, not completely understood, 
the mechanism of development is thought to be linked to vasoactive substances, 
including serotonin, released by metastatic tumour cells in the liver which are able to 
reach the right side of the heart. Distinctive carcinoid plaques are found throughout 
the endocardium of the right heart. The functional consequence of which typically 
leads to tricuspid and pulmonary valvulopathy. 
Much of our current understanding of carcinoid heart disease is based on 
retrospective studies conducted over 2 decades ago (5,6,19,20,24,25). There have 
been significant advances since this time. New therapeutic agents and anti-tumour 
treatment modalities including somatostatin analogues, interferon, targeted 
radionuclide therapy as well as small molecules have emerged.  The ability of these 
agents to modulate production of  tumour metabolites may alter  the development  of 
carcinoid heart disease.  We undertook a large, prospective, observational cohort 
study to define the prevalence, clinical features, diagnostic biomarkers, 
echocardiographic details and risk factors for development of carcinoid heart disease 
as well as evaluate the outcomes of cardiac surgery for carcinoid heart disease. 
 
7.1 CLINICAL FEATURES  
 
The prevalence of carcinoid heart disease amongst patients with carcinoid 
syndrome has been reported to occur in up to  66% of cases (5,56). These studies 
have been based on retrospective reviews of patients referred for echocardiography. 
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Limitations of this type of study include selection bias as clinicians may only refer for 
echocardiography when clinical symptoms or physical examination suggests cardiac 
involvement. Therefore, we do not believe they represent the true prevalence of 
carcinoid heart disease as not all patients are screened. 
Approximately 20% of patients present with carcinoid heart disease (74). 
Although symptomatic relief of severe valvular dysfunction is achieved by valve 
replacement surgery, right ventricular dysfunction does not improve post operatively 
and impaired right ventricular dysfunction is a predictor of poor prognosis (42). 
Therefore an early diagnosis of carcinoid heart disease prior to the onset of right 
ventricular dysfunction is desirable. 
In our study (Chapter 2) we found 27% of patients with moderate or severe 
valvular dysfunction (tricuspid regurgitation) were initially in NYHA Class 1. 
Secondly, 37% of patients did not display clinical signs suggestive of cardiac 
disease.  The study screened a cohort of patients of carcinoid syndrome irrespective 
of signs or symptoms of cardiac involvement. This suggests a significant proportion 
of patients may have sub-clinical valvular disease.  This supports the need for 
screening patients with carcinoid syndrome for carcinoid heart disease in order to 
reach a timely diagnosis prior to onset of right ventricular dysfunction. 
 The prevalence of carcinoid heart disease in our cohort was only 20%. This is 
substantially lower than previously reported. The reason for the change is not fully 
clear. However it may related to the higher use of somatotatsin analogue in the 
current cohort of patients compared to previous studies conducted a decade occur 
where the use of somatostatin analogue was much less liberal. 
 
 
128 
 
7.2 THE ROLE OF CARDIAC BIOMARKERS (N-TERMINAL BRAIN NATRIURETIC 
PEPTIDES) 
 
B-type natriuretic peptide (BNP) and its N-terminal fragment (NT-proBNP) are 
neurohormones  synthesized and secreted from ventricular myocardium (21). 
Median levels of NT-proBNP are higher in patients with carcinoid heart disease than 
those with only carcinoid syndrome (7). This may be explained by right ventricular 
dysfunction secondary to carcinoid valvular dysfunction. It is unclear whether NT-
proBNP can be used as a biomarker of the onset of early carcinoid valvular 
dysfunction. In our study (Chapter 3) elevation of NT-proBNP above 260pg/ml had 
excellent sensitivity and specificity for the diagnosis of carcinoid heart disease. 
Furthermore the level of NT-proBNP correlated with severity of carcinoid heart 
disease and functional NHYA class. In Chapter 1, we proposed all patients with 
carcinoid syndrome be regularly screened for the development of carcinoid heart 
disease. We suggest a possible strategy would be screen patients who are 
completely asymptomatic be using NT-proBNP and only those with elevated levels 
undergo echocardiography. 
 
7.3 THE ROLE OF CARDIAC IMAGING IN CARCINOID HEART DISEASE 
 
 Two dimensional echocardiographic features of carcinoid heart disease have 
been well described in several series (5,25,56). Typical features include thickened 
valve leaflets together with retraction, shortening and reduced excursion of valve 
leaflets.  The limitation of all 2D cross sectional imaging is only partial visualisation of 
the tricuspid and pulmonary valve is achieved as only one or two leaflets can be 
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identified. Secondly, there is limited data on asymptomatic patients where the pattern 
of disease may be different. 
 Our study (chapter 4) describes the echocardiographic features utilising 2D 
and 3D TTE as well as, in selected patients, 3D TEE and CMR. Transoesphageal 
techniques resolved the problem of limited acoustic windows and poor visualisation 
of right sided heart valves encountered with transthoracic techniques. 3D techniques 
produced an en-face view of the all three valve leaflet/cusps simultaneously. This 
allowed more detailed morphological assessment of each individual leaflet/cusp as 
well as coaptation between leaflets. Involvement of sub-valvular apparatus was 
identified and better characterised.  There was improved delineation of the spatial 
relationship between valve, sub-valvular apparatus and the endocardium of 
surrounding chambers.  CMR allowed better characterisation of myocardial 
metastases allowing measurement and assessment of invasion into surrounding 
structures. 
 Further research is needed to assess the optimal echocardiographic marker 
of right ventricular dysfunction. Data have emerged in other conditions which 
suggest identified 3D TTE quantification of RV dysfunction has good correlation to 
the current gold standard (CMR) (92). 
 
7.4 RISK FACTORS FOR THE DEVELOPMENT AND PROGRESSION OF CARCINOID 
HEART DISEASE 
 
 The pathogenesis of carcinoid heart disease is incompletely understood. 
Although serotonin is thought to be a key mediator a large proportion of patients with 
elevated levels of serotonin do not develop carcinoid heart disease. In Chapter 5, we 
identified a 5-HIAA > 300 μmols/24 hours and median daily flushing > 3 episodes 
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over 24 hours as being the greatest predictor of the development or progression of 
carcinoid heart disease. These two variables are potentially modifiable with anti-
tumour therapies. Currently, there are no guidelines with suggested targets for 5-
HIAA levels or symptom control. A trial would be needed to test the hypothesis that 
reduction to below these levels may reduce the risk of developing carcinoid heart 
disease.  
 A second observation from the study was the development of valvular 
dysfunction in carcinoid heart disease may be rapid. Patients could progress from 
trivial/mild to severe tricuspid regurgitation in less than 6 months. This highlights the 
need to close monitoring of patients with carcinoid syndrome for the development of 
cardiac disease. 
 
7.5 CLINICAL OUTCOMES AND COMPLICATIONS OF CARDIOVASCULAR  
SURGERY 
 
 The outcomes of medical management of carcinoid heart disease are poor. 
The Mayo clinic experience suggested the median survival of a patient treated 
medically was just 1.6 years based on data from the 1980‟s (5). Valve replacement 
surgery has been shown to offer symptomatic relief (defined as improvement in 
NYHA class) (38). The Mayo Clinic data also suggest there may be a survival 
advantage (41). In Chapter 6, we demonstrated a large proportion of patients are not 
actually suitable for valve replacement surgery due to uncontrolled symptoms of 
carcinoid syndrome, progressive tumour growth or other co-morbidities. In those that 
did undergo surgery, there was an improvement in functional status post valve 
surgery. Peri-operative mortality was high (30 day mortality 18.2%). 2 year survival 
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was only 44.4%. The majority of deaths were due to tumour related complications. 
This suggests although valve replacement therapy is an option in select patients a 
better strategy may to try to identify targets to prevent development of  cardiac 
disease in the first place. As identified in Chapter 5, control of tumour metabolites is 
the key to this strategy. 
 
7.6 CONCLUSION 
 
 The prevalence of carcinoid heart  disease has decreased from over 60% in 
historical series to under 20%. 
 Clinical correlates (functional NYHA class and clinical examination) are poor 
markers of early cardiac involvement in patients with carcinoid syndrome. 
Screening is required to identify patients with carcinoid heart disease. 
 NT-proBNP correlates with both severity of carcinoid heart disease, and 
functional class. A high sensitivity and specificity may allow its use a 
screening marker to target the use of echocardiography. 
 Characterisation of valvular involvement in patients with carcinoid syndrome is 
better defined with the use of three dimensional echocardiography than two 
dimensional techniques. 
 The risk of developing carcinoid heart disease is greatest in  patients with a 5-
HIAA  and greater than 3 flushing episodes per day. Further studies are 
desirable to assess whether modulation of these variables reduces the risk of  
developing carcinoid heart disease. 
 Cardiac valve surgery in carcinoid heart disease is associated with high peri-
operative risk although significant functional improvement occurs in those that 
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survive the surgery. Long term mortality is influenced more by tumour factors 
than traditional cardiac markers.  
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Royal Free Hospital 
Pond Street 
London  NW3 2QG 
 
Tel: 020 7794 0500 
Fax: 020 7830 2468 
Department of Cardiology  
CONSENT FORM (Confidential) 
 
Title of project: Carcinoid Heart Disease: Prevalence, progression and 
treatment. 
Name of Researchers: Dr J Davar, Dr S Bhattacharyya 
Any questions to Dr. S. Bhattachayya, Department of Cardiology, Royal Free 
Hospital, Pond Street, London.NW3 2JN. Telephone 02077940500 extn  33573 
 
    Please initial box 
 
1. I confirm that I have read and understood the information sheet for 
the above study and have had the opportunity to ask questions. 
 
 
   
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my 
medical care or legal rights being affected. 
 
   
3. I understand that sections of any of my medical notes may be looked 
at by regulatory authorities where it is relevant to my taking part in 
research.  I give permission for these individuals to have access to 
my records. 
 
   
 
4. 
 
I agree to take part in the above study. 
 
 
 
 
_____________________________ _________________  ____________________ 
Name of patient   Date    Signature 
 
 
 
________________________________ ___________________  ______________________ 
Name of Person taking consent  Date    Signature 
(if different from researcher) 
 
 
 
___________________________________ _____________________  _________________________ 
Researcher    Date    Signature 
 
 
1 for Patient; 1 for Researcher; 1 to be kept with hospital notes 
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Royal Free Hospital 
Pond Street 
London  NW3 2QG 
 
Tel: 020 7794 0500 
Fax: 020 7830 2468 
 
Department of Cardiology 
Dr Joseph Davar  
 
 
 
 
Patient information sheet  
 
 
Study title :  Carcinoid Heart Disease. Prevalence, progression and treatment. 
 
 
How common is carcinoid heart disease in patients with carcinoid , what factors affect its 
progression and how can we better treat our patients. 
 
Principal investigator:   
Dr J Davar 
Department of Cardiology, Royal Free Hospital, London, NW3 2QG 
Tel: 020 7794 0500 extension 33573 
 
 
 
 
We would like to invite you to take part in a research study.  Before you decide whether to 
take part, it is important for you to understand why the research is being done and what it 
will involve.  Please take time to read the following information carefully and discuss it with 
friends, relatives and your GP if you wish.  Ask us if there is anything that is not clear or if 
you would like more information.  Take time to decide whether or not you wish to take part. 
 
Consumers for Ethics in Research (CERES) publish a leaflet entitled “Medical Research and 
You”.  This leaflet gives more information about medical research and looks at some 
questions you may want to ask.  A copy may be obtained from CERES, PO Box 1365, 
London  N16 0BW.    
 
Thank you for reading this. 
 
What is the purpose of the study? 
 
We are interested in the development  of heart disease in patients with carcinoid disease.  
Some patients with carcinoid may develop a problem with  the heart valves.  In some 
patients, this may be serious leading to breathlessness  although there may be several 
other, unrelated causes of these symptoms.  The aim of the study, which will take place 
over two years, is to find out how common heart problems are in patients with carcinoid 
syndrome and if we can predict who will develop heart disease.  We will see if the heart is 
involved by doing an ultrasound scan of the heart.  This is called an echocardiogram and is 
similar to the type of scan that pregnant women have to see how their baby is growing. We 
will try to identify which patients may develop heart problems using simple blood and urine 
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tests. In certain patients who have involvement of the heart valves we routinely organise a 
special test called left and right heart catheterisation to measure the pressures of the right 
side of the heart and look for narrowing of the arteries that supply blood to the heart. We 
would want to take extra blood tests during this procedure to try to identify why the heart 
valves are affected. We would also organise a special ultrasound of the heart where you a 
given a medication to speed up your heart rate to assess how well your heart contracts and 
how good the blood supply to the heart is. 
 
 
Why have I been chosen? 
 
Because you have carcinoid disease we are interested to know whether your heart is 
affected and if so, to what degree. 
 
Do I have to take part? 
 
No, and if you do not want to join in the study, we will of course be pleased to look after 
you.  Even if you do decide to take part, you can always leave the study at any time.  Most 
of the tests are part of the usual care you would have. 
 
What will happen to me if I take part? 
 
You will be followed up and treated in the Neuroendocrine Tumour clinic by the 
neuroendocrine tumour unit team and by the cardiologists.  We will take a history from you 
and examine you. You will have a detailed heart ultrasound scan which you may have 
already had in the past.  This is a completely harmless test and quite interesting and you 
will be able to see the pumping action of your heart and hear blood flowing around your 
heart if you wish.   The test takes around 30 minutes.  You will also have some blood  and 
urine tests which are part of the routine tests we do for patients with carcinoid disease. If 
you have carcinoid heart valve disease we will ask you undergo cardiac catheterisation of 
the right and left heart.  This test measures pressures in the right side of the heart and 
looks for narrowing of the arteries of the heart. This is a routine test in people who have 
heart valve involvement with carcinoid as it helps decide how to manage each patient. You 
will also have a special ultrasound of the heart called a stress echo which helps us know 
how strong your heart muscle is and how good the blood supply to your heart muscle is. 
 
What are the possible benefits of taking part? 
 
The results of this study may help not only you but also other patients like you who have 
carcinoid disease. 
 
What if something goes wrong? 
 
The chances of something going wrong as a result of the study are no greater than if you 
were not taking part. If something did go wrong as a result of the study, there are no special 
compensation arrangements.  If you are harmed due to someone’s negligence then you have 
grounds for legal action.  Regardless of this, if you have any cause to complain about any 
aspect of the way you have been approached or treated, the normal NHS complaints 
mechanism is open to you.   
 
If you decide to join in, then, if you agree, we will also write to you GP surgery to inform 
them that you are part of our study and that we have asked your permission and you have 
agreed to participate.  We will also write to any other doctor who looks after you to inform 
them too if you agree. 
 
 
 
 
Will my taking part in this study be kept confidential? 
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All information collected about you will be kept strictly confidential.  Any information about 
you which leaves the hospital will have your name and address removed so that you cannot 
be recognised from it. 
 
What will happen to the results of the research study? 
 
The results will be analysed and may then be published in the medical literature.  This may 
take some time (1-2 years) after the study is completed.  You will not be identified in any 
report or publication. 
 
Who has reviewed the study? 
 
This study has been reviewed by the Royal Free Hospital NHS Local Research Ethics 
Committee.   
 
Thank you for reading this information sheet. 
  
 
We would like you to have two tests. 
  
 1. Heart ultrasound scan 
We are interested in performing an ultrasound scan of your heart to examine whether your 
heart may be affected.  This takes around 45 minutes and involves putting some harmless 
gel on the skin of your chest and then placing a probe on the skin to produce an image of 
your heart on a TV screen.  We also measure pressures in your heart and you may hear a 
whooshing noise as the probe detects the flow of blood in your heart. We will place a small , 
sterile plastic tube into a vein your hand. This feels no different to the sharp pin prick you 
feel when you have blood taken. A special sterile solution is passed into this tube over a few 
seconds and travels to the heart. This allows us to look at the heart wall between two 
chambers of the heart better than we can with the ultrasound alone. 
 
2. Blood tests and urine tests 
Finally, we would like to take some blood samples and this is no different or extra from the 
samples we would usually take in patients with carcinoid disease. 
 
Patients who are found to have carcinoid involvement of the heart valves will be 
asked to undergo two further tests in order to decide how best to manage them 
 
 
3.  Cardiac Catheterisation.  
 In patients who have heart valve involvement by carcinoid we routinely measure the 
pressures of the right side of the heart and take pictures of the arteries that supply blood to 
the heart. This involves coming to hospital for half a day. The procedure lasts about half an 
hour and is carried out under local anaesthetic. A small tube in placed into a vein and 
artery at the top of your right leg. You should not feel anything as local anaesthetic is put in 
the area first. Then a tiny tube is passed into the right side of the heart to measure the 
pressures in the right side of the heart. Some blood samples will be taken to help us find 
out why carcinoid affects the heart. A tiny tube is passed to the left side of the heart. Then a 
special dye (contrast) is used to take pictures of the arteries that supply blood to the heart. 
This procedure uses a special scanner which uses special radiation beams to take pictures. 
The amount of radiation you receive is equivalent to three plain x-rays of the bottom of your 
spine. Even if you decided not to take  part in this research, if you had heart involvement by 
carcinoid, you would still undergo this test. Therefore there is no extra risk by taking part 
in the research. 
 
 
 
4. Stress Echocardiogram and Tissue Doppler Echocardiogram 
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 In patients who have heart valve involvement by carcinoid we routinely see how 
strong your heart muscle is and  how good the blood supply to the heart muscle is. This 
involves putting a small plastic tube into a vein in your arm. A special mediation that 
speeds up your heart   goes through the plastic tube into you. An ultrasound picture of 
your heart is taken. This involves putting some harmless gel on the skin of your chest and 
then placing a probe on the skin to produce an image of your heart. This allows us to 
measure how strong your heart is when your heart is beating faster than normal. 
 
We will be keeping a close eye on you in clinic and will be available to answer any questions 
you have.  We will also be pleased to inform you of the results of the tests and keep you 
informed of the results of our investigations.  
 
 
 
 
Contact for further information: 
 
To get answers to questions about the research and your rights as a patient in the study 
please contact the persons. 
 
 
Dr Sanjeev Bhattacharyya, Cardiology Research Fellow, Telephone 020 7794 0500, ask to 
bleep 1048 
 
Dr Joseph Davar, Consultant Cardiologist, Royal Free Hospital. Telephone: 020 7794 0500 
extension 33573. 
 
Dr Martyn Caplin, Lead Clinician Neuroendocrine Tumour Unit, Royal Free Hospital. 
Telephone: 0207 830 2867 
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Royal Free Hospital 
Pond Street 
London  NW3 2QG 
 
Cardiology  
Dr Joseph Davar MD PhD 
Consultant Cardiologist 
Tel: 020 7794 0500 Extension: 33573 
 
Date: 
 
 
 
 
General Practitioner’s letter regarding 
Carcinoid Heart Disease: Prevalence, progression and treatment. 
 
Dear Dr ------------- 
 
We are interested in investigating the prevalence , natural progression, markers of 
progression and markers of improved outcome post cardiac valve surgery in patient 
with carcinoid disease who develop carcinoid heart disease.   Your patient, Mr/Mrs    
----------------- of -----------------    has consented us to write to you to inform you that 
she has agreed to be part of this long term study.   The tests performed are all part 
of the routine clinical care of patients with carcinoid disease and suspected cardiac 
involvement. 
  
 
It is not a drug trial.  All patients will be seen and examined by both an 
gastroenterologist and cardiologist. They will have an echocardiogram to investigate 
whether they have carcinoid heart disease at set intervals as well as blood tests  and 
urinary tests. Patient who need cardiac valve surgery will undergo right heart and left 
heart catheterisation and a stress echocardiogram. A special blood test to measure 
serotonin levels and NT-proBNP levels in the blood will be taken during cardiac 
catheterisation. 
 
We will keep you posted, as usual about their clinical condition and their medication.  
Please contact us if you have any questions.  
 
Yours sincerely, 
 
 
 
 
Dr Joseph Davar MD, PhD 
Consultant Cardiologist 
Lead Investigator 
Appendix III: Letter to General Practitioner 
